US20040242566A1 - Dipeptidyl peptidase inhibitors - Google Patents
Dipeptidyl peptidase inhibitors Download PDFInfo
- Publication number
- US20040242566A1 US20040242566A1 US10/809,638 US80963804A US2004242566A1 US 20040242566 A1 US20040242566 A1 US 20040242566A1 US 80963804 A US80963804 A US 80963804A US 2004242566 A1 US2004242566 A1 US 2004242566A1
- Authority
- US
- United States
- Prior art keywords
- phenyl
- group
- alkyl
- substituted
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [1*]N1CC([3*])=C([4*])N=C1[2*] Chemical compound [1*]N1CC([3*])=C([4*])N=C1[2*] 0.000 description 76
- ITNUSAQDNSHELQ-UHFFFAOYSA-N CC.CC.CC.CC.CC(C)(C)N1CCC1.CC(C)(C)N1CCCC1.CC(C)(C)N1CCCCC1.CC(C)(C)N1CCCCCC1 Chemical compound CC.CC.CC.CC.CC(C)(C)N1CCC1.CC(C)(C)N1CCCC1.CC(C)(C)N1CCCCC1.CC(C)(C)N1CCCCCC1 ITNUSAQDNSHELQ-UHFFFAOYSA-N 0.000 description 3
- OBXOEFSUKLJMBX-UHFFFAOYSA-N CC.CC.CC.CC.CC.CC(C)(C)C1CC1.CC(C)(C)C1CCC1.CC(C)(C)C1CCCC1.CC(C)(C)C1CCCCC1.CC(C)(C)C1CCCCCC1 Chemical compound CC.CC.CC.CC.CC.CC(C)(C)C1CC1.CC(C)(C)C1CCC1.CC(C)(C)C1CCCC1.CC(C)(C)C1CCCCC1.CC(C)(C)C1CCCCCC1 OBXOEFSUKLJMBX-UHFFFAOYSA-N 0.000 description 3
- YFUALNVUFBMQHG-UHFFFAOYSA-N CN1C=NC2=C1N=C(Cl)N(CC1=C(C#N)C=CC=C1)C2=O Chemical compound CN1C=NC2=C1N=C(Cl)N(CC1=C(C#N)C=CC=C1)C2=O YFUALNVUFBMQHG-UHFFFAOYSA-N 0.000 description 3
- SBHSYHCAANIRDS-MRXNPFEDSA-N CC(C)N1C(C(F)(F)F)=NC2=C1N=C(N1CCC[C@@H](N)C1)N(CC1=CC=CC=C1C#N)C2=O Chemical compound CC(C)N1C(C(F)(F)F)=NC2=C1N=C(N1CCC[C@@H](N)C1)N(CC1=CC=CC=C1C#N)C2=O SBHSYHCAANIRDS-MRXNPFEDSA-N 0.000 description 2
- NWUMSVVAWYHSEZ-QGZVFWFLSA-N CC(C)N1C=NC2=C1C(=O)N(CC1=C(C#N)C=CC=C1)C(N1CCC[C@@H](N)C1)=N2 Chemical compound CC(C)N1C=NC2=C1C(=O)N(CC1=C(C#N)C=CC=C1)C(N1CCC[C@@H](N)C1)=N2 NWUMSVVAWYHSEZ-QGZVFWFLSA-N 0.000 description 2
- GFDFINQSCGJTCD-UHFFFAOYSA-N CN1C=NC2=C1N=C(Cl)NC2=O Chemical compound CN1C=NC2=C1N=C(Cl)NC2=O GFDFINQSCGJTCD-UHFFFAOYSA-N 0.000 description 2
- BROCCMHDEBWCSI-UHFFFAOYSA-N CN1C=NC2=C1N=C(N1CCCC(N)C1)N(CC1=C(C#N)C=CC=C1)C2=O Chemical compound CN1C=NC2=C1N=C(N1CCCC(N)C1)N(CC1=C(C#N)C=CC=C1)C2=O BROCCMHDEBWCSI-UHFFFAOYSA-N 0.000 description 2
- KRGXLLJLTVEDKH-UHFFFAOYSA-N COC(=O)CNCC1=NC2=CC=CC=C2C(=O)N1C1=CC=CC=C1 Chemical compound COC(=O)CNCC1=NC2=CC=CC=C2C(=O)N1C1=CC=CC=C1 KRGXLLJLTVEDKH-UHFFFAOYSA-N 0.000 description 2
- PHJKYNSEJIZCAD-UHFFFAOYSA-N COC1=C(OC)C=C2C(=O)N(CC3=C(C#N)C=CC=C3)C(N3CCCC(N)C3)=NC2=C1 Chemical compound COC1=C(OC)C=C2C(=O)N(CC3=C(C#N)C=CC=C3)C(N3CCCC(N)C3)=NC2=C1 PHJKYNSEJIZCAD-UHFFFAOYSA-N 0.000 description 2
- DZNPOCHJCGTGCP-UHFFFAOYSA-N COC1=C2N=C(Cl)N=C(Cl)C2=CC=C1 Chemical compound COC1=C2N=C(Cl)N=C(Cl)C2=CC=C1 DZNPOCHJCGTGCP-UHFFFAOYSA-N 0.000 description 2
- QYOZNVCKISSENR-MRXNPFEDSA-N COC1=CC2=C(C=C1F)N=C(N1CCC[C@@H](N)C1)N(CC1=C(C#N)C=CC=C1)C2=O Chemical compound COC1=CC2=C(C=C1F)N=C(N1CCC[C@@H](N)C1)N(CC1=C(C#N)C=CC=C1)C2=O QYOZNVCKISSENR-MRXNPFEDSA-N 0.000 description 2
- FFJSFGYZQBJBIL-UHFFFAOYSA-N N#CC1=C(CN2C(=O)C3=C(C=CC=C3F)N=C2Cl)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=C(C=CC=C3F)N=C2Cl)C=CC=C1 FFJSFGYZQBJBIL-UHFFFAOYSA-N 0.000 description 2
- FUPNDDLNUDYQGX-UHFFFAOYSA-N N#CC1=C(CN2C(=O)C3=C(C=NC(Cl)=C3)N=C2Cl)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=C(C=NC(Cl)=C3)N=C2Cl)C=CC=C1 FUPNDDLNUDYQGX-UHFFFAOYSA-N 0.000 description 2
- ZDNJBEHOOQZWKQ-OAHLLOKOSA-N N#CC1=C(CN2C(=O)C3=C(C=NC(Cl)=C3)N=C2N2CCC[C@@H](N)C2)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=C(C=NC(Cl)=C3)N=C2N2CCC[C@@H](N)C2)C=CC=C1 ZDNJBEHOOQZWKQ-OAHLLOKOSA-N 0.000 description 2
- IZVBVAHHSUXPDZ-UHFFFAOYSA-N N#CC1=C(CN2C(=O)C3=C(N=C2Cl)N(COCC2=CC=CC=C2)C=N3)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=C(N=C2Cl)N(COCC2=CC=CC=C2)C=N3)C=CC=C1 IZVBVAHHSUXPDZ-UHFFFAOYSA-N 0.000 description 2
- XMOSOHDOZCRMML-UHFFFAOYSA-N N#CC1=C(CN2C(=O)C3=CC(F)=CC=C3N=C2N2CCCC(N)C2)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=CC(F)=CC=C3N=C2N2CCCC(N)C2)C=CC=C1 XMOSOHDOZCRMML-UHFFFAOYSA-N 0.000 description 2
- OYNURZXTLNNKAP-UHFFFAOYSA-N N#CC1=C(CN2C(=O)C3=CC=CC=C3N=C2N2CCCC(N)C2)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=CC=CC=C3N=C2N2CCCC(N)C2)C=CC=C1 OYNURZXTLNNKAP-UHFFFAOYSA-N 0.000 description 2
- BNRLRXYKCMEVFH-OAHLLOKOSA-N NC(=O)C1=C(CN2C(=O)C3=CC(F)=CC=C3N=C2N2CCC[C@@H](N)C2)C=CC=C1 Chemical compound NC(=O)C1=C(CN2C(=O)C3=CC(F)=CC=C3N=C2N2CCC[C@@H](N)C2)C=CC=C1 BNRLRXYKCMEVFH-OAHLLOKOSA-N 0.000 description 2
- IJLOKQRIYWHQDV-UHFFFAOYSA-N NCC1=NC2=CC=CC=C2C(=O)N1C1=C(Cl)C=C(Cl)C=C1 Chemical compound NCC1=NC2=CC=CC=C2C(=O)N1C1=C(Cl)C=C(Cl)C=C1 IJLOKQRIYWHQDV-UHFFFAOYSA-N 0.000 description 2
- WRPUZMBZIAGKBE-UHFFFAOYSA-N NCC1=NC2=CC=CC=C2C(=O)N1C1=C(Cl)C=CC=C1 Chemical compound NCC1=NC2=CC=CC=C2C(=O)N1C1=C(Cl)C=CC=C1 WRPUZMBZIAGKBE-UHFFFAOYSA-N 0.000 description 2
- CZRPKCIAWIDQLI-UHFFFAOYSA-N NCC1=NC2=CC=CC=C2C(=O)N1C1=CC=CC=C1 Chemical compound NCC1=NC2=CC=CC=C2C(=O)N1C1=CC=CC=C1 CZRPKCIAWIDQLI-UHFFFAOYSA-N 0.000 description 2
- QVEOGGYGCHHHHK-OAHLLOKOSA-N N[C@@H]1CCCN(C2=NC3=C(C=C(F)C=C3)C(=O)N2CC2=C(C(F)(F)F)C=CC=C2)C1 Chemical compound N[C@@H]1CCCN(C2=NC3=C(C=C(F)C=C3)C(=O)N2CC2=C(C(F)(F)F)C=CC=C2)C1 QVEOGGYGCHHHHK-OAHLLOKOSA-N 0.000 description 2
- KZOUNLZLYUDZPW-UHFFFAOYSA-N O=C1NC(Cl)=NC2=C(Cl)C=CC=C12 Chemical compound O=C1NC(Cl)=NC2=C(Cl)C=CC=C12 KZOUNLZLYUDZPW-UHFFFAOYSA-N 0.000 description 2
- WMEGBAASRUTYQN-UHFFFAOYSA-N O=C1NC(Cl)=NC2=CC(Cl)=CC=C12 Chemical compound O=C1NC(Cl)=NC2=CC(Cl)=CC=C12 WMEGBAASRUTYQN-UHFFFAOYSA-N 0.000 description 2
- GOXIUQBNDATVMB-UHFFFAOYSA-N CC(C)N1C(C(F)(F)F)=NC2=C1N=C(Br)N(CC1=CC=CC=C1C#N)C2=O Chemical compound CC(C)N1C(C(F)(F)F)=NC2=C1N=C(Br)N(CC1=CC=CC=C1C#N)C2=O GOXIUQBNDATVMB-UHFFFAOYSA-N 0.000 description 1
- OUDLCWVQKJVOOM-UHFFFAOYSA-N CC(C)N1C(C(F)(F)F)=NC2=C1N=C(N)N(CC1=CC=CC=C1C#N)C2=O Chemical compound CC(C)N1C(C(F)(F)F)=NC2=C1N=C(N)N(CC1=CC=CC=C1C#N)C2=O OUDLCWVQKJVOOM-UHFFFAOYSA-N 0.000 description 1
- NYCZFZFDICQHLD-UHFFFAOYSA-N CC(C)N1C(C(F)(F)F)=NC2=C1N=C(N)NC2=O Chemical compound CC(C)N1C(C(F)(F)F)=NC2=C1N=C(N)NC2=O NYCZFZFDICQHLD-UHFFFAOYSA-N 0.000 description 1
- CNYHXCROGLKAFF-UHFFFAOYSA-N CC(C)NC1=C(N)C(Cl)=NC(N)=N1 Chemical compound CC(C)NC1=C(N)C(Cl)=NC(N)=N1 CNYHXCROGLKAFF-UHFFFAOYSA-N 0.000 description 1
- LTOUEVLICAKMSS-UHFFFAOYSA-N CCCN1C=NC2=C1C(=O)N(CC1=C(C#N)C=CC=C1)C(Cl)=N2 Chemical compound CCCN1C=NC2=C1C(=O)N(CC1=C(C#N)C=CC=C1)C(Cl)=N2 LTOUEVLICAKMSS-UHFFFAOYSA-N 0.000 description 1
- LHORSDZODQQSGX-QGZVFWFLSA-N CCCN1C=NC2=C1C(=O)N(CC1=C(C#N)C=CC=C1)C(N1CCC[C@@H](N)C1)=N2 Chemical compound CCCN1C=NC2=C1C(=O)N(CC1=C(C#N)C=CC=C1)C(N1CCC[C@@H](N)C1)=N2 LHORSDZODQQSGX-QGZVFWFLSA-N 0.000 description 1
- WAGOURVKFTZAPV-UHFFFAOYSA-N CCCN1C=NC2=C1C(=O)NC(Cl)=N2 Chemical compound CCCN1C=NC2=C1C(=O)NC(Cl)=N2 WAGOURVKFTZAPV-UHFFFAOYSA-N 0.000 description 1
- FZNYAHNQXFHJIT-UHFFFAOYSA-N CCCN1C=NC2=C1N=C(Cl)N(CC1=C(C#N)C=CC=C1)C2=O Chemical compound CCCN1C=NC2=C1N=C(Cl)N(CC1=C(C#N)C=CC=C1)C2=O FZNYAHNQXFHJIT-UHFFFAOYSA-N 0.000 description 1
- YRIILLUALAPYMQ-UHFFFAOYSA-N CCCN1C=NC2=C1N=C(Cl)NC2=O Chemical compound CCCN1C=NC2=C1N=C(Cl)NC2=O YRIILLUALAPYMQ-UHFFFAOYSA-N 0.000 description 1
- MKCRRRIQPWISKM-QGZVFWFLSA-N CCCN1C=NC2=C1N=C(N1CCC[C@@H](N)C1)N(CC1=C(C#N)C=CC=C1)C2=O Chemical compound CCCN1C=NC2=C1N=C(N1CCC[C@@H](N)C1)N(CC1=C(C#N)C=CC=C1)C2=O MKCRRRIQPWISKM-QGZVFWFLSA-N 0.000 description 1
- RIKFCGUVGJBRTC-UHFFFAOYSA-N CCNCC1=NC2=CC=CC=C2C(=O)N1C1=CC=CC=C1 Chemical compound CCNCC1=NC2=CC=CC=C2C(=O)N1C1=CC=CC=C1 RIKFCGUVGJBRTC-UHFFFAOYSA-N 0.000 description 1
- KTZUDYFJBKRWLQ-QGZVFWFLSA-N CCOC(=O)C1=C(CN2C(=O)C3=CC(F)=CC=C3N=C2N2CCC[C@@H](N)C2)C=CC=C1 Chemical compound CCOC(=O)C1=C(CN2C(=O)C3=CC(F)=CC=C3N=C2N2CCC[C@@H](N)C2)C=CC=C1 KTZUDYFJBKRWLQ-QGZVFWFLSA-N 0.000 description 1
- BKYDTTDAZVVMJC-QGZVFWFLSA-N CCOC(=O)C1=C(CN2C(=O)C3=CC(OC)=C(OC)C=C3N=C2N2CCC[C@@H](N)C2)C=CC=C1 Chemical compound CCOC(=O)C1=C(CN2C(=O)C3=CC(OC)=C(OC)C=C3N=C2N2CCC[C@@H](N)C2)C=CC=C1 BKYDTTDAZVVMJC-QGZVFWFLSA-N 0.000 description 1
- AACLHXXAERSYEC-UHFFFAOYSA-N CN1C=NC2=C1C(=O)N(CC1=C(C#N)C=CC=C1)C(Cl)=N2 Chemical compound CN1C=NC2=C1C(=O)N(CC1=C(C#N)C=CC=C1)C(Cl)=N2 AACLHXXAERSYEC-UHFFFAOYSA-N 0.000 description 1
- AWXIQULCAMORLS-UHFFFAOYSA-N CN1C=NC2=C1C(=O)N(CC1=C(C#N)C=CC=C1)C(N1CCCC(N)C1)=N2 Chemical compound CN1C=NC2=C1C(=O)N(CC1=C(C#N)C=CC=C1)C(N1CCCC(N)C1)=N2 AWXIQULCAMORLS-UHFFFAOYSA-N 0.000 description 1
- HTRDGUDBXFNIOU-UHFFFAOYSA-N CN1C=NC2=C1C(=O)NC(Cl)=N2 Chemical compound CN1C=NC2=C1C(=O)NC(Cl)=N2 HTRDGUDBXFNIOU-UHFFFAOYSA-N 0.000 description 1
- HVMUWHZAZGTMJK-UHFFFAOYSA-N CN1C=NC2=C1C(Cl)=NC(Cl)=N2 Chemical compound CN1C=NC2=C1C(Cl)=NC(Cl)=N2 HVMUWHZAZGTMJK-UHFFFAOYSA-N 0.000 description 1
- HWMJNDVUIMQFEW-UHFFFAOYSA-N CN1C=NC2=C1N=C(Cl)N=C2Cl Chemical compound CN1C=NC2=C1N=C(Cl)N=C2Cl HWMJNDVUIMQFEW-UHFFFAOYSA-N 0.000 description 1
- BROCCMHDEBWCSI-OAHLLOKOSA-N CN1C=NC2=C1N=C(N1CCC[C@@H](N)C1)N(CC1=C(C#N)C=CC=C1)C2=O Chemical compound CN1C=NC2=C1N=C(N1CCC[C@@H](N)C1)N(CC1=C(C#N)C=CC=C1)C2=O BROCCMHDEBWCSI-OAHLLOKOSA-N 0.000 description 1
- KMMSRPSEYSNHKS-UHFFFAOYSA-N CN1N=C2N=C(Cl)N(CC3=C(C#N)C=CC=C3)C(=O)C2=N1 Chemical compound CN1N=C2N=C(Cl)N(CC3=C(C#N)C=CC=C3)C(=O)C2=N1 KMMSRPSEYSNHKS-UHFFFAOYSA-N 0.000 description 1
- IDKNNHNCRJXXGQ-CQSZACIVSA-N CN1N=C2N=C(N3CCC[C@@H](N)C3)N(CC3=C(C#N)C=CC=C3)C(=O)C2=N1 Chemical compound CN1N=C2N=C(N3CCC[C@@H](N)C3)N(CC3=C(C#N)C=CC=C3)C(=O)C2=N1 IDKNNHNCRJXXGQ-CQSZACIVSA-N 0.000 description 1
- GPKDTAWDHRASQV-UHFFFAOYSA-N CN1N=NC2=C1C(=O)N(CC1=C(C#N)C=CC=C1)C(Cl)=N2 Chemical compound CN1N=NC2=C1C(=O)N(CC1=C(C#N)C=CC=C1)C(Cl)=N2 GPKDTAWDHRASQV-UHFFFAOYSA-N 0.000 description 1
- MQVCRPIJVIXYAY-CQSZACIVSA-N CN1N=NC2=C1C(=O)N(CC1=C(C#N)C=CC=C1)C(N1CCC[C@@H](N)C1)=N2 Chemical compound CN1N=NC2=C1C(=O)N(CC1=C(C#N)C=CC=C1)C(N1CCC[C@@H](N)C1)=N2 MQVCRPIJVIXYAY-CQSZACIVSA-N 0.000 description 1
- COQJDXLULWNGBV-UHFFFAOYSA-N CN1N=NC2=C1C(=O)NC(Cl)=N2 Chemical compound CN1N=NC2=C1C(=O)NC(Cl)=N2 COQJDXLULWNGBV-UHFFFAOYSA-N 0.000 description 1
- YRSRYQUPSRYKMF-UHFFFAOYSA-N COC1=C(OC)C=C2C(=O)N(CC3=C(C#N)C=CC=C3)C(Cl)=NC2=C1 Chemical compound COC1=C(OC)C=C2C(=O)N(CC3=C(C#N)C=CC=C3)C(Cl)=NC2=C1 YRSRYQUPSRYKMF-UHFFFAOYSA-N 0.000 description 1
- LYGNYEAKOKLTQD-UHFFFAOYSA-N COC1=C(OC)C=C2C(=O)N(CC3=C(C#N)C=CC=C3)C(N3CCCCC3)=NC2=C1 Chemical compound COC1=C(OC)C=C2C(=O)N(CC3=C(C#N)C=CC=C3)C(N3CCCCC3)=NC2=C1 LYGNYEAKOKLTQD-UHFFFAOYSA-N 0.000 description 1
- RZWQZIHZLKTUAX-OAHLLOKOSA-N COC1=C(OC)C=C2C(=O)N(CC3=C(C(=O)O)C=CC=C3)C(N3CCC[C@@H](N)C3)=NC2=C1 Chemical compound COC1=C(OC)C=C2C(=O)N(CC3=C(C(=O)O)C=CC=C3)C(N3CCC[C@@H](N)C3)=NC2=C1 RZWQZIHZLKTUAX-OAHLLOKOSA-N 0.000 description 1
- WBUKJTXOCNSCRI-UHFFFAOYSA-N COC1=C(OC)C=C2C(=O)N(CC3=C([N+](=O)[O-])C=CC=C3)C(N3CCCC(N)C3)=NC2=C1 Chemical compound COC1=C(OC)C=C2C(=O)N(CC3=C([N+](=O)[O-])C=CC=C3)C(N3CCCC(N)C3)=NC2=C1 WBUKJTXOCNSCRI-UHFFFAOYSA-N 0.000 description 1
- DBOAGRILJPETJN-UHFFFAOYSA-N COC1=C(OC)C=C2C(=O)NC(Cl)=NC2=C1 Chemical compound COC1=C(OC)C=C2C(=O)NC(Cl)=NC2=C1 DBOAGRILJPETJN-UHFFFAOYSA-N 0.000 description 1
- AKVMNOFHSRIGJD-UHFFFAOYSA-N COC1=C2N=C(Cl)N(CC3=C(C#N)C=CC=C3)C(=O)C2=CC=C1 Chemical compound COC1=C2N=C(Cl)N(CC3=C(C#N)C=CC=C3)C(=O)C2=CC=C1 AKVMNOFHSRIGJD-UHFFFAOYSA-N 0.000 description 1
- UBWUNMXPUUXQRB-UHFFFAOYSA-N COC1=C2N=C(Cl)NC(=O)C2=CC=C1 Chemical compound COC1=C2N=C(Cl)NC(=O)C2=CC=C1 UBWUNMXPUUXQRB-UHFFFAOYSA-N 0.000 description 1
- CWYRIAXMURYWCO-UHFFFAOYSA-N COC1=C2N=C(N3CCCC(N)C3)N(CC3=C(C#N)C=CC=C3)C(=O)C2=CC=C1 Chemical compound COC1=C2N=C(N3CCCC(N)C3)N(CC3=C(C#N)C=CC=C3)C(=O)C2=CC=C1 CWYRIAXMURYWCO-UHFFFAOYSA-N 0.000 description 1
- JOUZPZZMCYIDOW-UHFFFAOYSA-N COC1=C2NC(=O)NC(=O)C2=CC=C1 Chemical compound COC1=C2NC(=O)NC(=O)C2=CC=C1 JOUZPZZMCYIDOW-UHFFFAOYSA-N 0.000 description 1
- MEUAHQGXXXZIGQ-UHFFFAOYSA-N COC1=CC2=C(C=C1F)N=C(Cl)N(CC1=C(C#N)C=CC=C1)C2=O Chemical compound COC1=CC2=C(C=C1F)N=C(Cl)N(CC1=C(C#N)C=CC=C1)C2=O MEUAHQGXXXZIGQ-UHFFFAOYSA-N 0.000 description 1
- OOEXOSAASFBGID-UHFFFAOYSA-N COC1=CC2=C(C=C1F)NC(=O)NC2=O Chemical compound COC1=CC2=C(C=C1F)NC(=O)NC2=O OOEXOSAASFBGID-UHFFFAOYSA-N 0.000 description 1
- VIXHCGWFUITEHO-UHFFFAOYSA-N COC1=CC2=C(C=C1F)NC(Cl)NC2=O Chemical compound COC1=CC2=C(C=C1F)NC(Cl)NC2=O VIXHCGWFUITEHO-UHFFFAOYSA-N 0.000 description 1
- MUYAGELFKQAAKM-UHFFFAOYSA-N COC1=CC2=C(C=N1)N=C(Cl)NC2=O Chemical compound COC1=CC2=C(C=N1)N=C(Cl)NC2=O MUYAGELFKQAAKM-UHFFFAOYSA-N 0.000 description 1
- BKDANTHIHWWSIU-MRXNPFEDSA-N COC1=CC2=C(C=N1)N=C(N1CCC[C@@H](N)C1)N(CC1=C(C#N)C=CC=C1)C2=O Chemical compound COC1=CC2=C(C=N1)N=C(N1CCC[C@@H](N)C1)N(CC1=C(C#N)C=CC=C1)C2=O BKDANTHIHWWSIU-MRXNPFEDSA-N 0.000 description 1
- OTJZCIIGEIOJAB-UHFFFAOYSA-N COC1=CC2=C(C=N1)NC(=O)NC2=O Chemical compound COC1=CC2=C(C=N1)NC(=O)NC2=O OTJZCIIGEIOJAB-UHFFFAOYSA-N 0.000 description 1
- NGWOMNGDMOOJQD-UHFFFAOYSA-N COC1=CC=C2N=C(Cl)N(CC3=C(C#N)C=CC=C3)C(=O)C2=C1 Chemical compound COC1=CC=C2N=C(Cl)N(CC3=C(C#N)C=CC=C3)C(=O)C2=C1 NGWOMNGDMOOJQD-UHFFFAOYSA-N 0.000 description 1
- WEAMQTSRMCCGSJ-UHFFFAOYSA-N COC1=CC=C2N=C(Cl)N=C(Cl)C2=C1 Chemical compound COC1=CC=C2N=C(Cl)N=C(Cl)C2=C1 WEAMQTSRMCCGSJ-UHFFFAOYSA-N 0.000 description 1
- RZBPTLOVZCUBRS-UHFFFAOYSA-N COC1=CC=C2N=C(Cl)NC(=O)C2=C1 Chemical compound COC1=CC=C2N=C(Cl)NC(=O)C2=C1 RZBPTLOVZCUBRS-UHFFFAOYSA-N 0.000 description 1
- KEHDIZISMAQBKX-QGZVFWFLSA-N COC1=CC=C2N=C(N3CCC[C@@H](N)C3)N(CC3=C(C#N)C=CC=C3)C(=O)C2=C1 Chemical compound COC1=CC=C2N=C(N3CCC[C@@H](N)C3)N(CC3=C(C#N)C=CC=C3)C(=O)C2=C1 KEHDIZISMAQBKX-QGZVFWFLSA-N 0.000 description 1
- KAYIYDVQBAPJIU-UHFFFAOYSA-N COC1=CC=C2NC(=O)NC(=O)C2=C1 Chemical compound COC1=CC=C2NC(=O)NC(=O)C2=C1 KAYIYDVQBAPJIU-UHFFFAOYSA-N 0.000 description 1
- ZKHSEKCVLBFMPC-UHFFFAOYSA-N ClC1=NC2=C(C(Cl)=N1)N(COCC1=CC=CC=C1)C=N2 Chemical compound ClC1=NC2=C(C(Cl)=N1)N(COCC1=CC=CC=C1)C=N2 ZKHSEKCVLBFMPC-UHFFFAOYSA-N 0.000 description 1
- YNXUTUJCKRGCDF-UHFFFAOYSA-N ClC1=NC2=C(N=CN2COCC2=CC=CC=C2)C(Cl)=N1 Chemical compound ClC1=NC2=C(N=CN2COCC2=CC=CC=C2)C(Cl)=N1 YNXUTUJCKRGCDF-UHFFFAOYSA-N 0.000 description 1
- TUQSVSYUEBNNKQ-UHFFFAOYSA-N ClC1=NC2=CC=CC=C2C(Cl)=N1 Chemical compound ClC1=NC2=CC=CC=C2C(Cl)=N1 TUQSVSYUEBNNKQ-UHFFFAOYSA-N 0.000 description 1
- UQRIJFZITLGMMH-UHFFFAOYSA-N FC1=C(N2CCOCC2)C=C2N=C(Cl)N=C(Cl)C2=C1 Chemical compound FC1=C(N2CCOCC2)C=C2N=C(Cl)N=C(Cl)C2=C1 UQRIJFZITLGMMH-UHFFFAOYSA-N 0.000 description 1
- VLPYLGGGYDUVJN-UHFFFAOYSA-N FC1=CC=C2N=C(Cl)N=C(Cl)C2=C1 Chemical compound FC1=CC=C2N=C(Cl)N=C(Cl)C2=C1 VLPYLGGGYDUVJN-UHFFFAOYSA-N 0.000 description 1
- WYEIHVJOOZCGMD-UHFFFAOYSA-N N#CC1=C(CN2C(=O)C3=C(C=CC(Cl)=C3)N=C2Cl)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=C(C=CC(Cl)=C3)N=C2Cl)C=CC=C1 WYEIHVJOOZCGMD-UHFFFAOYSA-N 0.000 description 1
- LGQVNFUOFPCSSQ-QGZVFWFLSA-N N#CC1=C(CN2C(=O)C3=C(C=CC(Cl)=C3)N=C2N2CCC[C@@H](N)C2)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=C(C=CC(Cl)=C3)N=C2N2CCC[C@@H](N)C2)C=CC=C1 LGQVNFUOFPCSSQ-QGZVFWFLSA-N 0.000 description 1
- QPRAFCFDOZPSSH-MRXNPFEDSA-N N#CC1=C(CN2C(=O)C3=C(C=CC=C3F)N=C2N2CCC[C@@H](N)C2)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=C(C=CC=C3F)N=C2N2CCC[C@@H](N)C2)C=CC=C1 QPRAFCFDOZPSSH-MRXNPFEDSA-N 0.000 description 1
- RVKPXEKZGYUJGV-LJQANCHMSA-N N#CC1=C(CN2C(=O)C3=C(C=NC(N4CCCC4)=C3)N=C2N2CCC[C@@H](N)C2)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=C(C=NC(N4CCCC4)=C3)N=C2N2CCC[C@@H](N)C2)C=CC=C1 RVKPXEKZGYUJGV-LJQANCHMSA-N 0.000 description 1
- YNXONNBNBVMGSA-UHFFFAOYSA-N N#CC1=C(CN2C(=O)C3=C(CCCC3)N=C2Cl)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=C(CCCC3)N=C2Cl)C=CC=C1 YNXONNBNBVMGSA-UHFFFAOYSA-N 0.000 description 1
- OKCMFIHLRVWIAX-QGZVFWFLSA-N N#CC1=C(CN2C(=O)C3=C(CCCC3)N=C2N2CCC[C@@H](N)C2)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=C(CCCC3)N=C2N2CCC[C@@H](N)C2)C=CC=C1 OKCMFIHLRVWIAX-QGZVFWFLSA-N 0.000 description 1
- PEYKMURDQIETBV-UHFFFAOYSA-N N#CC1=C(CN2C(=O)C3=C(N=C2Cl)NC=N3)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=C(N=C2Cl)NC=N3)C=CC=C1 PEYKMURDQIETBV-UHFFFAOYSA-N 0.000 description 1
- MTLWGWAQKONZAZ-UHFFFAOYSA-N N#CC1=C(CN2C(=O)C3=C(N=C2N2CCCC(N)C2)NC=N3)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=C(N=C2N2CCCC(N)C2)NC=N3)C=CC=C1 MTLWGWAQKONZAZ-UHFFFAOYSA-N 0.000 description 1
- HRWZZIDXRWCPGE-UHFFFAOYSA-N N#CC1=C(CN2C(=O)C3=C(N=CN3)N=C2N2CCCCC(N)C2)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=C(N=CN3)N=C2N2CCCCC(N)C2)C=CC=C1 HRWZZIDXRWCPGE-UHFFFAOYSA-N 0.000 description 1
- XGNJBDGMUPSHHV-OAQYLSRUSA-N N#CC1=C(CN2C(=O)C3=C(N=CN3CC3=CC=CC=C3)N=C2N2CCC[C@@H](N)C2)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=C(N=CN3CC3=CC=CC=C3)N=C2N2CCC[C@@H](N)C2)C=CC=C1 XGNJBDGMUPSHHV-OAQYLSRUSA-N 0.000 description 1
- DWGOGRBGKKQVPH-UHFFFAOYSA-N N#CC1=C(CN2C(=O)C3=C(N=CN3COCC3=CC=CC=C3)N=C2Cl)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=C(N=CN3COCC3=CC=CC=C3)N=C2Cl)C=CC=C1 DWGOGRBGKKQVPH-UHFFFAOYSA-N 0.000 description 1
- DPJXTBPIDMNEQR-UHFFFAOYSA-N N#CC1=C(CN2C(=O)C3=CC(Br)=CC=C3N=C2Cl)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=CC(Br)=CC=C3N=C2Cl)C=CC=C1 DPJXTBPIDMNEQR-UHFFFAOYSA-N 0.000 description 1
- SNDYOAGMAZLRJN-QGZVFWFLSA-N N#CC1=C(CN2C(=O)C3=CC(Br)=CC=C3N=C2N2CCC[C@@H](N)C2)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=CC(Br)=CC=C3N=C2N2CCC[C@@H](N)C2)C=CC=C1 SNDYOAGMAZLRJN-QGZVFWFLSA-N 0.000 description 1
- HPPZRDBLJGBNLP-MRXNPFEDSA-N N#CC1=C(CN2C(=O)C3=CC(Br)=CC=C3N=C2N2CC[C@@H](N)C2)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=CC(Br)=CC=C3N=C2N2CC[C@@H](N)C2)C=CC=C1 HPPZRDBLJGBNLP-MRXNPFEDSA-N 0.000 description 1
- OPWOBXFAGILIMQ-UHFFFAOYSA-N N#CC1=C(CN2C(=O)C3=CC(Cl)=CC(Cl)=C3N=C2Cl)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=CC(Cl)=CC(Cl)=C3N=C2Cl)C=CC=C1 OPWOBXFAGILIMQ-UHFFFAOYSA-N 0.000 description 1
- CCCCRDFOGIQSFC-MRXNPFEDSA-N N#CC1=C(CN2C(=O)C3=CC(Cl)=CC(Cl)=C3N=C2N2CCC[C@@H](N)C2)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=CC(Cl)=CC(Cl)=C3N=C2N2CCC[C@@H](N)C2)C=CC=C1 CCCCRDFOGIQSFC-MRXNPFEDSA-N 0.000 description 1
- FEEGAFMXBGNXRF-UHFFFAOYSA-N N#CC1=C(CN2C(=O)C3=CC(F)=C(N4CCOCC4)C=C3N=C2Cl)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=CC(F)=C(N4CCOCC4)C=C3N=C2Cl)C=CC=C1 FEEGAFMXBGNXRF-UHFFFAOYSA-N 0.000 description 1
- SUVWKEOODLERME-LJQANCHMSA-N N#CC1=C(CN2C(=O)C3=CC(F)=C(N4CCOCC4)C=C3N=C2N2CCC[C@@H](N)C2)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=CC(F)=C(N4CCOCC4)C=C3N=C2N2CCC[C@@H](N)C2)C=CC=C1 SUVWKEOODLERME-LJQANCHMSA-N 0.000 description 1
- XMOSOHDOZCRMML-QGZVFWFLSA-N N#CC1=C(CN2C(=O)C3=CC(F)=CC=C3N=C2N2CCC[C@@H](N)C2)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=CC(F)=CC=C3N=C2N2CCC[C@@H](N)C2)C=CC=C1 XMOSOHDOZCRMML-QGZVFWFLSA-N 0.000 description 1
- SQTAAJRXWPIWMS-UHFFFAOYSA-N N#CC1=C(CN2C(=O)C3=CC=C(Cl)C=C3N=C2Cl)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=CC=C(Cl)C=C3N=C2Cl)C=CC=C1 SQTAAJRXWPIWMS-UHFFFAOYSA-N 0.000 description 1
- IPGJEBMBCSCKBX-UHFFFAOYSA-N N#CC1=C(CN2C(=O)C3=CC=C(Cl)C=C3N=C2N2CCCC(N)C2)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=CC=C(Cl)C=C3N=C2N2CCCC(N)C2)C=CC=C1 IPGJEBMBCSCKBX-UHFFFAOYSA-N 0.000 description 1
- GXDMWXPYCUYFDK-UHFFFAOYSA-N N#CC1=C(CN2C(=O)C3=CC=CC(Cl)=C3N=C2Cl)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=CC=CC(Cl)=C3N=C2Cl)C=CC=C1 GXDMWXPYCUYFDK-UHFFFAOYSA-N 0.000 description 1
- OBBPMZQSYHHZLS-UHFFFAOYSA-N N#CC1=C(CN2C(=O)C3=CC=CC(Cl)=C3N=C2N2CCCC(N)C2)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=CC=CC(Cl)=C3N=C2N2CCCC(N)C2)C=CC=C1 OBBPMZQSYHHZLS-UHFFFAOYSA-N 0.000 description 1
- PKZCPYLESZUUQC-UHFFFAOYSA-N N#CC1=C(CN2C(=O)C3=CC=CC=C3N=C2Cl)C=CC=C1 Chemical compound N#CC1=C(CN2C(=O)C3=CC=CC=C3N=C2Cl)C=CC=C1 PKZCPYLESZUUQC-UHFFFAOYSA-N 0.000 description 1
- ZYUBFUSTEUXALN-JOCHJYFZSA-N N#CC1=CC=CC=C1CN1C=NC2=C1N=C(N1CCC[C@@H](N)C1)N(CC1=C(C#N)C=CC=C1)C2=O Chemical compound N#CC1=CC=CC=C1CN1C=NC2=C1N=C(N1CCC[C@@H](N)C1)N(CC1=C(C#N)C=CC=C1)C2=O ZYUBFUSTEUXALN-JOCHJYFZSA-N 0.000 description 1
- PNCVVGLYHYAREA-UHFFFAOYSA-N N#CC1=NC2=CC=C(F)C=C2C(=O)N1CC1=C(C#N)C=CC=C1 Chemical compound N#CC1=NC2=CC=C(F)C=C2C(=O)N1CC1=C(C#N)C=CC=C1 PNCVVGLYHYAREA-UHFFFAOYSA-N 0.000 description 1
- RFAOIEGCQIHVFX-UHFFFAOYSA-N NCC1=NC2=CC=CC=C2C(=O)N1C1=CC=C(Cl)C=C1 Chemical compound NCC1=NC2=CC=CC=C2C(=O)N1C1=CC=C(Cl)C=C1 RFAOIEGCQIHVFX-UHFFFAOYSA-N 0.000 description 1
- CBJCDJBSALMONM-OAHLLOKOSA-N N[C@@H]1CCCN(C2=NC3=CC=C(F)C=C3C(=O)N2CC2=C(C(=O)O)C=CC=C2)C1 Chemical compound N[C@@H]1CCCN(C2=NC3=CC=C(F)C=C3C(=O)N2CC2=C(C(=O)O)C=CC=C2)C1 CBJCDJBSALMONM-OAHLLOKOSA-N 0.000 description 1
- FAWBUJXBEJHHAL-UHFFFAOYSA-N O=C(O)CNCC1=NC2=CC=CC=C2C(=O)N1C1=CC=CC=C1 Chemical compound O=C(O)CNCC1=NC2=CC=CC=C2C(=O)N1C1=CC=CC=C1 FAWBUJXBEJHHAL-UHFFFAOYSA-N 0.000 description 1
- BFPKYURZJADNQY-UHFFFAOYSA-N O=C1C2=C(C=CC(F)=C2)N=C(Cl)N1CC1=C(C(F)(F)F)C=CC=C1 Chemical compound O=C1C2=C(C=CC(F)=C2)N=C(Cl)N1CC1=C(C(F)(F)F)C=CC=C1 BFPKYURZJADNQY-UHFFFAOYSA-N 0.000 description 1
- JZDVFUAHGLJVQG-UHFFFAOYSA-N O=C1NC(=O)C2=CC(Br)=CC=C2N1 Chemical compound O=C1NC(=O)C2=CC(Br)=CC=C2N1 JZDVFUAHGLJVQG-UHFFFAOYSA-N 0.000 description 1
- VOIFPEGZIPOIGK-UHFFFAOYSA-N O=C1NC(=O)C2=CC(Cl)=CC(Cl)=C2N1 Chemical compound O=C1NC(=O)C2=CC(Cl)=CC(Cl)=C2N1 VOIFPEGZIPOIGK-UHFFFAOYSA-N 0.000 description 1
- MVCDFHYCPSGVFF-UHFFFAOYSA-N O=C1NC(=O)C2=CC(F)=C(F)C=C2N1 Chemical compound O=C1NC(=O)C2=CC(F)=C(F)C=C2N1 MVCDFHYCPSGVFF-UHFFFAOYSA-N 0.000 description 1
- NWSOQOWZWZFLGA-UHFFFAOYSA-N O=C1NC(=O)C2=CC(F)=C(N3CCOCC3)C=C2N1 Chemical compound O=C1NC(=O)C2=CC(F)=C(N3CCOCC3)C=C2N1 NWSOQOWZWZFLGA-UHFFFAOYSA-N 0.000 description 1
- QUQJMNPJMVUMNE-UHFFFAOYSA-N O=C1NC(=O)C2=CC(F)=CC=C2N1 Chemical compound O=C1NC(=O)C2=CC(F)=CC=C2N1 QUQJMNPJMVUMNE-UHFFFAOYSA-N 0.000 description 1
- GYFANIZCMKHHKV-UHFFFAOYSA-N O=C1NC(=O)C2C=C(=O)N=CC2N1 Chemical compound O=C1NC(=O)C2C=C(=O)N=CC2N1 GYFANIZCMKHHKV-UHFFFAOYSA-N 0.000 description 1
- HMMCJGFXJDVXFQ-UHFFFAOYSA-N O=C1NC(Cl)=NC2=C(Cl)C=C(Cl)C=C12 Chemical compound O=C1NC(Cl)=NC2=C(Cl)C=C(Cl)C=C12 HMMCJGFXJDVXFQ-UHFFFAOYSA-N 0.000 description 1
- WZPNWJJWUJAWSZ-UHFFFAOYSA-N O=C1NC(Cl)=NC2=C1C(F)=CC=C2 Chemical compound O=C1NC(Cl)=NC2=C1C(F)=CC=C2 WZPNWJJWUJAWSZ-UHFFFAOYSA-N 0.000 description 1
- SHJZIBHISYWVLR-UHFFFAOYSA-N O=C1NC(Cl)=NC2=C1C=C(Cl)C=C2 Chemical compound O=C1NC(Cl)=NC2=C1C=C(Cl)C=C2 SHJZIBHISYWVLR-UHFFFAOYSA-N 0.000 description 1
- YMTFDJKNHRRGHU-UHFFFAOYSA-N O=C1NC(Cl)=NC2=C1C=C(Cl)N=C2 Chemical compound O=C1NC(Cl)=NC2=C1C=C(Cl)N=C2 YMTFDJKNHRRGHU-UHFFFAOYSA-N 0.000 description 1
- LIERYUHZPPRHIS-UHFFFAOYSA-N O=C1NC(Cl)=NC2=C1CCCC2 Chemical compound O=C1NC(Cl)=NC2=C1CCCC2 LIERYUHZPPRHIS-UHFFFAOYSA-N 0.000 description 1
- ZXMQNKIZUBHRLM-UHFFFAOYSA-N O=C1NC(Cl)=NC2=C1N(COCC1=CC=CC=C1)C=N2 Chemical compound O=C1NC(Cl)=NC2=C1N(COCC1=CC=CC=C1)C=N2 ZXMQNKIZUBHRLM-UHFFFAOYSA-N 0.000 description 1
- NOZVZORABSGLTM-UHFFFAOYSA-N O=C1NC(Cl)=NC2=C1N=CN2COCC1=CC=CC=C1 Chemical compound O=C1NC(Cl)=NC2=C1N=CN2COCC1=CC=CC=C1 NOZVZORABSGLTM-UHFFFAOYSA-N 0.000 description 1
- BSBPYYNQMXBGIJ-UHFFFAOYSA-N O=C1NC(Cl)=NC2=CC(N3CCOCC3)=C(F)C=C12 Chemical compound O=C1NC(Cl)=NC2=CC(N3CCOCC3)=C(F)C=C12 BSBPYYNQMXBGIJ-UHFFFAOYSA-N 0.000 description 1
- WZVAPPYRAGWFKW-UHFFFAOYSA-N O=C1NC(Cl)=NC2=CC=C(Br)C=C12 Chemical compound O=C1NC(Cl)=NC2=CC=C(Br)C=C12 WZVAPPYRAGWFKW-UHFFFAOYSA-N 0.000 description 1
- CBHYEOLZQCLMSY-UHFFFAOYSA-N O=C1NC(Cl)=NC2=CC=C(F)C=C12 Chemical compound O=C1NC(Cl)=NC2=CC=C(F)C=C12 CBHYEOLZQCLMSY-UHFFFAOYSA-N 0.000 description 1
- CNGRGEDXKHIFIL-UHFFFAOYSA-N O=C1NC(Cl)=NC2=CC=CC=C12 Chemical compound O=C1NC(Cl)=NC2=CC=CC=C12 CNGRGEDXKHIFIL-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pregnancy & Childbirth (AREA)
- Child & Adolescent Psychology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/809,638 US20040242566A1 (en) | 2003-03-25 | 2004-03-24 | Dipeptidyl peptidase inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45778503P | 2003-03-25 | 2003-03-25 | |
US10/809,638 US20040242566A1 (en) | 2003-03-25 | 2004-03-24 | Dipeptidyl peptidase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040242566A1 true US20040242566A1 (en) | 2004-12-02 |
Family
ID=33131718
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/809,638 Abandoned US20040242566A1 (en) | 2003-03-25 | 2004-03-24 | Dipeptidyl peptidase inhibitors |
US10/809,637 Expired - Fee Related US7687625B2 (en) | 2003-03-25 | 2004-03-24 | Dipeptidyl peptidase inhibitors |
US10/809,636 Abandoned US20040242568A1 (en) | 2003-03-25 | 2004-03-24 | Dipeptidyl peptidase inhibitors |
US10/809,635 Expired - Fee Related US7550590B2 (en) | 2003-03-25 | 2004-03-24 | Dipeptidyl peptidase inhibitors |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/809,637 Expired - Fee Related US7687625B2 (en) | 2003-03-25 | 2004-03-24 | Dipeptidyl peptidase inhibitors |
US10/809,636 Abandoned US20040242568A1 (en) | 2003-03-25 | 2004-03-24 | Dipeptidyl peptidase inhibitors |
US10/809,635 Expired - Fee Related US7550590B2 (en) | 2003-03-25 | 2004-03-24 | Dipeptidyl peptidase inhibitors |
Country Status (7)
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US20080090845A1 (en) * | 2006-08-23 | 2008-04-17 | Neurogen Corporation | Haloalkyl-substituted pyrimidinone derivatives |
US20090069347A1 (en) * | 2006-08-23 | 2009-03-12 | Neurogen Corporation | 2-phenoxy pyrimidinone analogues |
US20090257979A1 (en) * | 2008-04-15 | 2009-10-15 | Intermune, Inc. | Novel Inhibitors of Hepatitis C Virus Replication |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7687625B2 (en) | 2003-03-25 | 2010-03-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7687638B2 (en) | 2004-06-04 | 2010-03-30 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
US7723344B2 (en) | 2003-08-13 | 2010-05-25 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7781584B2 (en) | 2004-03-15 | 2010-08-24 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7790734B2 (en) | 2003-09-08 | 2010-09-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7825242B2 (en) | 2004-07-16 | 2010-11-02 | Takeda Pharmaceutical Company Limted | Dipeptidyl peptidase inhibitors |
US7872124B2 (en) | 2004-12-21 | 2011-01-18 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US20110110890A1 (en) * | 2009-11-09 | 2011-05-12 | Intermune, Inc. | Novel Inhibitors of Hepatitis C Virus Replication |
US7960384B2 (en) | 2006-03-28 | 2011-06-14 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US8084605B2 (en) | 2006-11-29 | 2011-12-27 | Kelly Ron C | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
US8222411B2 (en) | 2005-09-16 | 2012-07-17 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
US8906901B2 (en) | 2005-09-14 | 2014-12-09 | Takeda Pharmaceutical Company Limited | Administration of dipeptidyl peptidase inhibitors |
US10555929B2 (en) | 2015-03-09 | 2020-02-11 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US11253508B2 (en) | 2017-04-03 | 2022-02-22 | Coherus Biosciences, Inc. | PPARy agonist for treatment of progressive supranuclear palsy |
Families Citing this family (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1911754B1 (en) * | 2003-08-13 | 2013-10-09 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
AR051596A1 (es) * | 2004-10-26 | 2007-01-24 | Irm Llc | Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios |
JP2008520744A (ja) | 2004-11-19 | 2008-06-19 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 抗炎症性ピラゾロピリミジン |
WO2007024993A2 (en) | 2005-08-26 | 2007-03-01 | Merck & Co., Inc. | Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
AU2011201488B2 (en) * | 2004-11-29 | 2011-11-17 | Merck Sharp & Dohme Corp. | Fused aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
MX2007009760A (es) | 2005-02-11 | 2007-11-07 | Amylin Pharmaceuticals Inc | Polipeptidos del analogo e hibrido del peptido inhibidor gastrico con propiedades seleccionables. |
WO2007022946A1 (de) | 2005-08-21 | 2007-03-01 | Abbott Gmbh & Co. Kg | Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren |
HRP20140091T4 (hr) † | 2005-09-14 | 2021-12-24 | Takeda Pharmaceutical Company Limited | Davanje inhibitora dipeptidil peptidaze |
CN101384594A (zh) * | 2005-12-23 | 2009-03-11 | 诺瓦提斯公司 | 用作dpp-iv抑制剂的稠合杂环化合物 |
JP2009531456A (ja) * | 2006-03-28 | 2009-09-03 | 武田薬品工業株式会社 | (r)−3−アミノピペリジン二塩酸塩の調製 |
AU2007347115A1 (en) | 2006-04-04 | 2008-10-23 | The Regents Of The University Of California | PI3 kinase antagonists |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
EA200802054A1 (ru) | 2006-04-12 | 2009-04-28 | Пробиодруг Аг | Ингибиторы фермента |
JP2010505811A (ja) | 2006-10-04 | 2010-02-25 | ファイザー・プロダクツ・インク | カルシウム受容体アンタゴニストとしてのピリド[4,3−d]ピリミジン−4(3H)−オン誘導体 |
JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての3−ヒドロキシ−1,5−ジヒドロ−ピロール−2−オン誘導体 |
US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
WO2008120813A1 (ja) | 2007-04-03 | 2008-10-09 | Mitsubishi Tanabe Pharma Corporation | ジペプチジルペプチダーゼ4阻害化合物と甘味料との併用 |
DK2142514T3 (da) | 2007-04-18 | 2015-03-23 | Probiodrug Ag | Thioureaderivater som glutaminylcyclase-inhibitorer |
ME00954B (me) | 2007-05-11 | 2012-06-20 | Pfizer | Aminoheterociklični spojevi |
GB2467670B (en) | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
KR101897881B1 (ko) | 2008-01-04 | 2018-09-12 | 인텔리카인, 엘엘씨 | 특정 화학 물질, 조성물 및 방법 |
WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
BRPI0915231A2 (pt) | 2008-07-08 | 2018-06-12 | Intellikine Inc | compostos inibidores de quinase e métodos de uso |
US20100029371A1 (en) * | 2008-08-01 | 2010-02-04 | Gennady Medvinsky | Personal Game Services Commerce System (PGSCS) |
US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
EP2358720B1 (en) | 2008-10-16 | 2016-03-02 | The Regents of The University of California | Fused ring heteroaryl kinase inhibitors |
US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
CN101817833B (zh) * | 2009-02-26 | 2013-03-06 | 中国科学院广州生物医药与健康研究院 | Dpp-iv抑制剂 |
EP2427195B1 (en) | 2009-05-07 | 2019-05-01 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
JP5934645B2 (ja) | 2009-09-11 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体 |
WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
KR101447789B1 (ko) | 2009-11-12 | 2014-10-06 | 에프. 호프만-라 로슈 아게 | N-7 치환된 퓨린 및 피라졸로피리미딘 화합물, 조성물 및 사용 방법 |
UA107100C2 (xx) | 2009-12-23 | 2014-11-25 | Конденсовані гетероароматичні піролідинони як інгібітори syk | |
CA2784799C (en) | 2009-12-30 | 2014-06-10 | Shanghai Fochon Pharmaceutical Co Ltd | Certain dipeptidyl peptidase inhibtors |
JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
CN102791704B (zh) | 2010-03-10 | 2015-11-25 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶(qc, ec 2.3.2.5)的杂环抑制剂 |
BR112012025592A2 (pt) | 2010-04-06 | 2019-09-24 | Arena Pharm Inc | moduladores do receptor de gpr119 e o tratamento de distúrbios relacionados com os mesmos |
EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
CN103002738A (zh) | 2010-05-21 | 2013-03-27 | 英特利凯恩有限责任公司 | 用于激酶调节的化学化合物、组合物和方法 |
CN102311448B (zh) * | 2010-07-07 | 2014-02-19 | 中国科学院广州生物医药与健康研究院 | 噻吩并嘧啶酮类dpp-iv抑制剂 |
CN102311447B (zh) * | 2010-07-07 | 2013-11-27 | 中国科学院广州生物医药与健康研究院 | 杂环并嘧啶酮类dpp-iv抑制剂 |
PE20131371A1 (es) | 2010-09-22 | 2013-11-25 | Arena Pharm Inc | Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este |
CN103298474B (zh) | 2010-11-10 | 2016-06-29 | 无限药品股份有限公司 | 杂环化合物及其用途 |
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
NZ612909A (en) | 2011-01-10 | 2015-09-25 | Infinity Pharmaceuticals Inc | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
AR085397A1 (es) | 2011-02-23 | 2013-09-25 | Intellikine Inc | Combinacion de inhibidores de quinasa y sus usos |
WO2012118945A2 (en) * | 2011-03-03 | 2012-09-07 | Merck Sharp & Dohme Corp. | Fused bicyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors |
JP6050264B2 (ja) | 2011-03-16 | 2016-12-21 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
EP2723739B1 (en) | 2011-06-22 | 2016-08-24 | Takeda Pharmaceutical Company Limited | Substituted 6-aza-isoindolin-1-one derivatives |
US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
MX2014000648A (es) | 2011-07-19 | 2014-09-25 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y sus usos. |
EP3392252B1 (en) | 2011-08-23 | 2023-10-04 | Libertas Bio, Inc. | Pyrimido- pyridazinone compounds and use thereof |
TW201311663A (zh) | 2011-08-29 | 2013-03-16 | Infinity Pharmaceuticals Inc | 雜環化合物及其用途 |
MX370814B (es) | 2011-09-02 | 2020-01-08 | Univ California | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
CN103130819B (zh) * | 2011-12-01 | 2016-01-20 | 中国科学院上海药物研究所 | 噻吩[3,2-d]并嘧啶-4-酮类化合物、其制备方法、药物组合物及用途 |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
UA117347C2 (uk) | 2012-06-13 | 2018-07-25 | Інсайт Холдинґс Корпорейшн | Заміщені трициклічні сполуки як інгібітори fgfr |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
RU2015115631A (ru) | 2012-09-26 | 2016-11-20 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Модулирование ire1 |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
CN105263931B (zh) | 2013-04-19 | 2019-01-25 | 因赛特公司 | 作为fgfr抑制剂的双环杂环 |
UY35675A (es) | 2013-07-24 | 2015-02-27 | Novartis Ag | Derivados sustituidos de quinazolin-4-ona |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
NZ718430A (en) | 2013-10-04 | 2021-12-24 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
WO2015053023A1 (ja) * | 2013-10-08 | 2015-04-16 | シャープ株式会社 | 画像表示装置 |
AU2015231413B2 (en) | 2014-03-19 | 2020-04-23 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of PI3K-gamma mediated disorders |
US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
KR101739003B1 (ko) * | 2014-07-11 | 2017-05-23 | 에스티팜 주식회사 | 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도 |
GB201415598D0 (en) | 2014-09-03 | 2014-10-15 | Univ Birmingham | Elavated Itercranial Pressure Treatment |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
UA121669C2 (uk) | 2015-02-20 | 2020-07-10 | Інсайт Корпорейшн | Біциклічні гетероцикли як інгібітори fgfr |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
MX2018003058A (es) | 2015-09-14 | 2018-08-01 | Infinity Pharmaceuticals Inc | Formas solidas de derivados de isoquinolinona, proceso de fabricacion, composiciones que las contienen y metodos de uso de las mismas. |
KR101730790B1 (ko) | 2015-12-24 | 2017-04-28 | 한국과학기술연구원 | 세로토닌 5-ht6 저해 활성을 갖는 5,6,7,8-테트라하이드로퀴나졸린-2-아민 화합물 |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
JP7054681B2 (ja) | 2016-06-24 | 2022-04-14 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 組合せ療法 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
MA52493A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Sels d'un inhibiteur de fgfr |
SG11202010636VA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Solid forms of an fgfr inhibitor and processes for preparing the same |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
PE20221085A1 (es) | 2019-10-14 | 2022-07-05 | Incyte Corp | Heterociclos biciclicos como inhibidores de fgfr |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
CN115151539A (zh) | 2019-12-04 | 2022-10-04 | 因赛特公司 | Fgfr抑制剂的衍生物 |
US20230054782A1 (en) * | 2019-12-18 | 2023-02-23 | Merck Sharp & Dohme Llc | Bicyclic heterocycle compounds methods of use thereof for the treatment of herpes viruses |
CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Citations (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3823135A (en) * | 1972-12-26 | 1974-07-09 | Shell Oil Co | Pyrimidone herbicides |
US3960949A (en) * | 1971-04-02 | 1976-06-01 | Schering Aktiengesellschaft | 1,2-Biguanides |
US4494978A (en) * | 1976-12-30 | 1985-01-22 | Chevron Research Company | Herbicidal N-(N'-hydrocarbyloxycarbamylalkyl)-2,6-dialkyl-alpha-haloacetanilides |
US4935493A (en) * | 1987-10-06 | 1990-06-19 | E. I. Du Pont De Nemours And Company | Protease inhibitors |
US5387512A (en) * | 1991-06-07 | 1995-02-07 | Merck & Co. Inc. | Preparation of 3-[z-benzoxazol-2-yl)ethyl]-5-(1-hydroxyethyl)-6-methyl-2-(1H)-pyridinone by biotransformation |
US5433955A (en) * | 1989-01-23 | 1995-07-18 | Akzo N.V. | Site specific in vivo activation of therapeutic drugs |
US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5614379A (en) * | 1995-04-26 | 1997-03-25 | Eli Lilly And Company | Process for preparing anti-obesity protein |
US5614492A (en) * | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US5624894A (en) * | 1992-09-17 | 1997-04-29 | University Of Florida | Brain-enhanced delivery of neuroactive peptides by sequential metabolism |
US5885997A (en) * | 1996-07-01 | 1999-03-23 | Dr. Reddy's Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
US6090786A (en) * | 1994-06-10 | 2000-07-18 | Fondatech Benelux N.V. | Serine proteases, their activity and their synthetic inhibitors |
US6172081B1 (en) * | 1999-06-24 | 2001-01-09 | Novartis Ag | Tetrahydroisoquinoline 3-carboxamide derivatives |
US6184020B1 (en) * | 1997-12-16 | 2001-02-06 | Novo Nordisk Biotech, Inc. | Polypeptides having aminopeptidase activity and nucleic acids encoding same |
US6201132B1 (en) * | 1993-12-03 | 2001-03-13 | Ferring B.V. | Inhibitors of DP-mediated processes, compositions, and therapeutic methods thereof |
US6214340B1 (en) * | 1997-11-18 | 2001-04-10 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Physiologically active substance sulphostin, process for producing the same, and use thereof |
US6235493B1 (en) * | 1997-08-06 | 2001-05-22 | The Regents Of The University Of California | Amino acid substituted-cresyl violet, synthetic fluorogenic substrates for the analysis of agents in individual in vivo cells or tissue |
US6251391B1 (en) * | 1999-10-01 | 2001-06-26 | Klaire Laboratories, Inc. | Compositions containing dipepitidyl peptidase IV and tyrosinase or phenylalaninase for reducing opioid-related symptons |
US6258597B1 (en) * | 1997-09-29 | 2001-07-10 | Point Therapeutics, Inc. | Stimulation of hematopoietic cells in vitro |
US6261794B1 (en) * | 1999-10-14 | 2001-07-17 | Saint Louis University | Methods for identifying inhibitors of methionine aminopeptidases |
US6265551B1 (en) * | 1995-06-01 | 2001-07-24 | Dana-Farber Cancer Institute, Inc. | Form of dipeptidylpeptidase IV (CD26) found in human serum, antibodies thereto, and uses thereof |
US20020006899A1 (en) * | 1998-10-06 | 2002-01-17 | Pospisilik Andrew J. | Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals |
US20020019411A1 (en) * | 2000-03-10 | 2002-02-14 | Robl Jeffrey A. | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
US6355614B1 (en) * | 1998-06-05 | 2002-03-12 | Point Therapeutics | Cyclic boroproline compounds |
US20020037829A1 (en) * | 2000-08-23 | 2002-03-28 | Aronson Peter S. | Use of DPPIV inhibitors as diuretic and anti-hypertensive agents |
US20020041871A1 (en) * | 2000-06-01 | 2002-04-11 | Brudnak Mark A. | Genomeceutical and/or enzymatic composition and method for treating autism |
US20020049164A1 (en) * | 1998-06-24 | 2002-04-25 | Hans-Ulrich Demuth | Prodrugs of DP IV-inhibitors |
US20020049153A1 (en) * | 1999-05-17 | 2002-04-25 | BRIDON Dominique P. | Long lasting insulinoptropic peptides |
US6380398B2 (en) * | 2000-01-04 | 2002-04-30 | Novo Nordisk A/S | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
US20020061839A1 (en) * | 1998-03-09 | 2002-05-23 | Scharpe Simon Lodewijk | Serine peptidase modulators |
US20020071838A1 (en) * | 1998-07-31 | 2002-06-13 | Hans-Ulrich Demuth | Method for raising the blood glucose level in mammals |
US20020077340A1 (en) * | 2000-11-20 | 2002-06-20 | Richard Sulsky | Pyridone inhibitors of fatty acid binding protein and method |
US20020082427A1 (en) * | 1999-06-10 | 2002-06-27 | Hans-Ulrich Demuth | Method for the production of thiazolidin |
US20020082292A1 (en) * | 2000-09-27 | 2002-06-27 | Sahoo Soumya P. | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
US20030008905A1 (en) * | 2000-03-31 | 2003-01-09 | Hans-Ulrich Demuth | Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
US20030008925A1 (en) * | 1997-11-19 | 2003-01-09 | Marc Esteve | Treatment of drug-induced sleepiness |
US20030027282A1 (en) * | 1997-10-06 | 2003-02-06 | Huber Brigitte T. | Quiescent cell dipeptidyl peptidase: a novel cytoplasmic serine protease |
US20030040478A1 (en) * | 1999-12-08 | 2003-02-27 | Drucker Daniel J | Chemotherapy treatment |
US20030045464A1 (en) * | 1997-12-16 | 2003-03-06 | Hermeling Ronald Norbert | Glucagon-like peptide-1 crystals |
US20030055052A1 (en) * | 2000-11-10 | 2003-03-20 | Stefan Peters | FAP-activated anti-tumor compounds |
US20030060412A1 (en) * | 2000-01-27 | 2003-03-27 | Prouty Walter Francis | Process for solubilizing glucagon-like peptide 1compounds |
US20030060434A1 (en) * | 1997-02-18 | 2003-03-27 | Loretta Nielsen | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms |
US20030069234A1 (en) * | 2001-06-06 | 2003-04-10 | Medina Julio C. | CXCR3 antagonists |
US6548481B1 (en) * | 1998-05-28 | 2003-04-15 | Probiodrug Ag | Effectors of dipeptidyl peptidase IV |
US20030087950A1 (en) * | 2001-03-28 | 2003-05-08 | Denanteuil Guillaume | New alpha-amino acid sulphonyl compounds |
US20030087935A1 (en) * | 1999-09-22 | 2003-05-08 | Cheng Peter T. | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
US20030092697A1 (en) * | 2001-05-30 | 2003-05-15 | Cheng Peter T. | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
US20030089935A1 (en) * | 2001-11-13 | 2003-05-15 | Macronix International Co., Ltd. | Non-volatile semiconductor memory device with multi-layer gate insulating structure |
US20030092630A2 (en) * | 1999-08-24 | 2003-05-15 | Probiodrug Ag | New effectors of dipeptidyl peptidase iv for topical use |
US20030096857A1 (en) * | 1999-11-30 | 2003-05-22 | Evans David Michael | Novel antidiabetic agents |
US20030100563A1 (en) * | 2001-07-06 | 2003-05-29 | Edmondson Scott D. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
US20030105077A1 (en) * | 2001-07-03 | 2003-06-05 | Kanstrup Anders Bendtz | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
US20030103968A1 (en) * | 2001-04-12 | 2003-06-05 | Andree Amelsberg | Use of alpha specific antibody BIBH1 in the treatment of cancer |
US20030119738A1 (en) * | 2001-09-06 | 2003-06-26 | Andre Niestroj | Novel inhibitors of dipeptidyl peptidase I |
US20030119750A1 (en) * | 2001-06-27 | 2003-06-26 | Hans-Ulrich Demuth | Use of dipeptidyl peptidase IV inhibitors |
US20030119736A1 (en) * | 2001-04-02 | 2003-06-26 | Hans-Ulrich Demuth | Methods for improving islet signaling in diabetes mellitus and for its prevention |
US20030125304A1 (en) * | 2001-11-09 | 2003-07-03 | Hans-Ulrich Demuth | Substituted amino ketone compounds |
US20030130306A1 (en) * | 2001-11-06 | 2003-07-10 | Pratik Devasthale | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
US20030130199A1 (en) * | 2001-06-27 | 2003-07-10 | Von Hoersten Stephan | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
US20030130281A1 (en) * | 2001-10-26 | 2003-07-10 | Markus Boehringer | DPP IV inhibitors |
US20030135023A1 (en) * | 2001-06-27 | 2003-07-17 | Hans-Ulrich Demuth | Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis |
US20030139434A1 (en) * | 2000-01-21 | 2003-07-24 | Bork Balkan | Combinations comprising dipeptidylpeptidase-iv inhibitor |
US20030139429A1 (en) * | 2001-09-27 | 2003-07-24 | Cohen David Saul | Combinations |
US20030144206A1 (en) * | 2001-12-29 | 2003-07-31 | Knudsen Lotte Bjerre | Combined use of a GLP-1 compound and modulator of diabetic late complications |
US6673829B2 (en) * | 2001-09-14 | 2004-01-06 | Novo Nordisk A/S | Aminoazetidine,-pyrrolidine and -piperidine derivatives |
US6686337B2 (en) * | 2000-10-30 | 2004-02-03 | Ortho-Mcneil Pharmaceutical, Inc. | Combination therapy comprising anti-diabetic and anticonvulsant agents |
US6706742B2 (en) * | 2001-05-15 | 2004-03-16 | Les Laboratories Servier | Alpha-amino-acid compounds |
US20040054171A1 (en) * | 2002-07-04 | 2004-03-18 | Jensen Anette Frost | Polymorphic forms of a 4H-thieno[3,2-E]-1,2,4-thiadiazine 1,1-dioxide derivative |
US6710040B1 (en) * | 2002-06-04 | 2004-03-23 | Pfizer Inc. | Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors |
US6710843B2 (en) * | 2001-06-19 | 2004-03-23 | Samsung Electronics Co., Ltd. | In-line system and method for manufacturing liquid crystal display |
US20040058876A1 (en) * | 2002-09-18 | 2004-03-25 | Torsten Hoffmann | Secondary binding site of dipeptidyl peptidase IV (DP IV) |
US6727261B2 (en) * | 2001-12-27 | 2004-04-27 | Hoffman-La Roche Inc. | Pyrido[2,1-A]Isoquinoline derivatives |
US6747035B2 (en) * | 2001-08-13 | 2004-06-08 | Warner-Lambert Llc | 1-alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors |
US20040110817A1 (en) * | 2002-11-18 | 2004-06-10 | Pfizer Inc | Dipeptidyl peptidase IV inhibiting fluorinated cyclic amides |
US20040116328A1 (en) * | 2002-06-06 | 2004-06-17 | Eisai Co., Ltd. | Condensed imidazole derivatives |
US20040132732A1 (en) * | 2002-10-21 | 2004-07-08 | Wei Han | Quinazolinones and derivatives thereof as factor Xa inhibitors |
US20040138148A1 (en) * | 2001-02-14 | 2004-07-15 | Nobuhiko Fushimi | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof |
US20050014732A1 (en) * | 2003-03-14 | 2005-01-20 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and an anti-diabetic agent |
US20050020574A1 (en) * | 2002-12-03 | 2005-01-27 | Boehringer Ingelheim Pharma Gmbh Co. Kg | New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions |
US20050026921A1 (en) * | 2003-06-18 | 2005-02-03 | Boehringer Ingelheim International Gmbh | New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
US20050032804A1 (en) * | 2003-06-24 | 2005-02-10 | Cypes Stephen Howard | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
US20050038020A1 (en) * | 2003-08-01 | 2005-02-17 | Hamann Lawrence G. | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
US20050043299A1 (en) * | 2001-10-23 | 2005-02-24 | Ferring B. V. | Inhibitors of dipeptidyl peptidase iv |
US20050043292A1 (en) * | 2003-08-20 | 2005-02-24 | Pfizer Inc | Fluorinated lysine derivatives as dipeptidyl peptidase IV inhibitors |
US6867205B2 (en) * | 2002-02-13 | 2005-03-15 | Hoffman-La Roche Inc. | Pyridine and pyrimidine derivatives |
US20050058635A1 (en) * | 2003-05-05 | 2005-03-17 | Hans-Ulrich Demuth | Use of effectors of glutaminyl and glutamate cyclases |
Family Cites Families (221)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US150344A (en) * | 1874-04-28 | Improvement in fluid-meters | ||
US150343A (en) * | 1874-04-28 | Ezra milleb | ||
US114141A (en) * | 1871-04-25 | Improvement in steam-traps | ||
US150353A (en) * | 1874-04-28 | Improvement in bearing-bars for furnace-grates | ||
CH317122A (de) * | 1952-09-03 | 1956-11-15 | Basf Ag | Verfahren zur Herstellung von Küpenfarbstoffen |
DE1249281B (US20040242566A1-20041202-C00155.png) | 1963-05-18 | |||
DE1670912C3 (de) | 1967-08-18 | 1981-06-11 | Bayer Ag, 5090 Leverkusen | Herbizide Mittel auf Basis von 1,2,4-Triazin-5-onen |
GB1377642A (en) * | 1971-01-14 | 1974-12-18 | Koninklijke Gist Spiritus | Penicillanic and cephalosporanic acid derivatives |
DE2150686A1 (de) | 1971-10-12 | 1973-04-19 | Basf Ag | 6-amino-uracil-5-carbonsaeurethioamide |
AU5996573A (en) | 1972-09-11 | 1975-03-06 | Commonwealth Scientific And Industrial Research Organisation | Pyridinium salts |
GB1464248A (en) | 1973-11-01 | 1977-02-09 | Ici Ltd | Substituted triazinediones their preparation and use as herbicides |
DE2361551A1 (de) | 1973-12-11 | 1975-06-19 | Basf Ag | Wasserloesliche azofarbstoffe |
DE2500024A1 (de) | 1975-01-02 | 1976-07-08 | Basf Ag | Wasserloesliche azofarbstoffe |
JPS535180A (en) | 1976-07-01 | 1978-01-18 | Sumitomo Chem Co Ltd | Preparation of 3,4-dihydro-2 (1h) quinazoline derivatives |
DE2720085A1 (de) | 1977-05-05 | 1978-11-16 | Hoechst Ag | Pyrimido(6,1-a)isochinolin-2-on- derivate |
CH657851A5 (de) | 1983-06-28 | 1986-09-30 | Ciba Geigy Ag | Chromogene chinazolonverbindungen. |
AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
DE3856378T2 (de) | 1987-09-04 | 2000-05-11 | Beecham Group Plc | Substituierte Thiazolidindionderivate |
GB8900382D0 (en) | 1989-01-09 | 1989-03-08 | Janssen Pharmaceutica Nv | 2-aminopyrimidinone derivatives |
IE63502B1 (en) | 1989-04-21 | 1995-05-03 | Zeneca Ltd | Aminopyrimidine derivatives useful for treating cardiovascular disorders |
US5366862A (en) | 1990-02-14 | 1994-11-22 | Receptor Laboratories, Inc. | Method for generating and screening useful peptides |
US5814460A (en) | 1990-02-14 | 1998-09-29 | Diatide, Inc. | Method for generating and screening useful peptides |
EP0442473B1 (en) | 1990-02-15 | 1998-08-19 | Takeda Chemical Industries, Ltd. | Pyrimidinedione derivatives, their production and use |
US5462928A (en) | 1990-04-14 | 1995-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type IV |
DE4110019C2 (de) | 1991-03-27 | 2000-04-13 | Merck Patent Gmbh | Imidazopyridine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen |
US6825169B1 (en) | 1991-10-22 | 2004-11-30 | Trustees Of Tufts College | Inhibitors of dipeptidyl-aminopeptidase type IV |
WO1993008259A2 (en) | 1991-10-22 | 1993-04-29 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type iv |
US5350752A (en) | 1991-12-16 | 1994-09-27 | E. R. Squibb & Sons, Inc. | Dihydropyrimidine derivatives |
DE4141788A1 (de) | 1991-12-18 | 1993-06-24 | Merck Patent Gmbh | Imidazopyridine |
CA2129337A1 (en) * | 1992-02-19 | 1993-09-02 | Jotham W. Coe | Heterocyclic compounds for enhancing antitumor activity |
DE4305602A1 (de) | 1992-06-17 | 1993-12-23 | Merck Patent Gmbh | Imidazopyridine |
IL106877A (en) | 1992-09-10 | 1998-03-10 | Lilly Co Eli | Rodinin derivatives for use as drugs for the treatment of Alzheimer's disease |
US5811281A (en) | 1993-07-12 | 1998-09-22 | Cornell Research Foundation, Inc. | Immortalized intestinal epithelial cell lines |
DE4341453A1 (de) | 1993-12-06 | 1995-06-08 | Merck Patent Gmbh | Imidazopyridine |
ATE202567T1 (de) | 1994-03-08 | 2001-07-15 | Otsuka Pharma Co Ltd | Phosphorsäurediester-derivate |
US5580979A (en) | 1994-03-15 | 1996-12-03 | Trustees Of Tufts University | Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions |
US5543396A (en) | 1994-04-28 | 1996-08-06 | Georgia Tech Research Corp. | Proline phosphonate derivatives |
US5601986A (en) * | 1994-07-14 | 1997-02-11 | Amgen Inc. | Assays and devices for the detection of extrahepatic biliary atresia |
DE4432860A1 (de) | 1994-09-15 | 1996-03-21 | Merck Patent Gmbh | Imidazopyridine |
US5879173A (en) * | 1995-01-13 | 1999-03-09 | Methode Electronics, Inc. | Removable transceiver module and receptacle |
US5734558A (en) * | 1995-01-13 | 1998-03-31 | Poplawski; Daniel S. | Removable optoelectronic module |
US5717533A (en) * | 1995-01-13 | 1998-02-10 | Methode Electronics Inc. | Removable optoelectronic module |
US5864468A (en) * | 1995-01-13 | 1999-01-26 | Methode Electronics, Inc. | Removable optoelectronic module with grounding means |
US6325989B1 (en) | 1995-06-01 | 2001-12-04 | Dana-Farber Cancer Institute, Inc. | Form of dipeptidylpeptidase IV (CD26) found in human serum |
ES2157366T3 (es) | 1995-06-09 | 2001-08-16 | Hoffmann La Roche | Derivados de pirimidindiona, pirimidintriona, triacindiona como antagonistas de receptores alfa-1-adrenergicos. |
JPH0928376A (ja) | 1995-07-21 | 1997-02-04 | Ajinomoto Co Inc | 新規ジペプチジルペプチダーゼivとその製造方法 |
TW445263B (en) * | 1996-02-29 | 2001-07-11 | Janssen Pharmaceutica Nv | Novel esters of 1,4-disubstituted piperidine derivatives |
DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
US5965532A (en) | 1996-06-28 | 1999-10-12 | Trustees Of Tufts College | Multivalent compounds for crosslinking receptors and uses thereof |
KR100579765B1 (ko) | 1996-07-01 | 2006-12-28 | 닥터 레디스 레보러터리즈 리미티드 | 신규헤테로고리형화합물의제조방법,이를함유하는약제조성물및당뇨병및이와관련된질병의치료에있어서그의용도 |
US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
US7235627B2 (en) | 1996-08-30 | 2007-06-26 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
GB9702701D0 (en) | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
JP3468007B2 (ja) * | 1997-02-05 | 2003-11-17 | 住友電装株式会社 | レバー式コネクタ |
US6100234A (en) | 1997-05-07 | 2000-08-08 | Tufts University | Treatment of HIV |
CN1227363C (zh) | 1997-05-16 | 2005-11-16 | 诺沃奇梅兹生物技术有限公司 | 具有脯氨酰二肽氨肽酶活性的多肽和编码该多肽的核酸 |
EP0897012A1 (en) | 1997-07-05 | 1999-02-17 | Societe Des Produits Nestle S.A. | Cloning of the prolyl-dipeptidyl-peptidase from aspergillus oryzae |
IL125950A0 (en) * | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
US6342611B1 (en) | 1997-10-10 | 2002-01-29 | Cytovia, Inc. | Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof |
WO1999038501A2 (en) | 1998-02-02 | 1999-08-05 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
FR2777283B1 (fr) | 1998-04-10 | 2000-11-24 | Adir | Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
US6129911A (en) | 1998-07-10 | 2000-10-10 | Rhode Island Hospital, A Lifespan Partner | Liver stem cell |
DE19844693A1 (de) * | 1998-09-29 | 2000-03-30 | Delphi Automotive Systems Gmbh | Zweiteiliger elektrischer Verbinder |
US20030176357A1 (en) | 1998-10-06 | 2003-09-18 | Pospisilik Andrew J. | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels |
CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
GB9906715D0 (en) | 1999-03-23 | 1999-05-19 | Ferring Bv | Compositions for promoting growth |
US6548529B1 (en) * | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
EP1171438A1 (en) | 1999-04-20 | 2002-01-16 | Novo Nordisk A/S | Compounds, their preparation and use |
US6107317A (en) | 1999-06-24 | 2000-08-22 | Novartis Ag | N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
US6110949A (en) | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
US6528486B1 (en) * | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
US6617340B1 (en) | 1999-07-29 | 2003-09-09 | Novartis Ag | N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
ES2272319T3 (es) * | 1999-08-27 | 2007-05-01 | Chemocentryx, Inc. | Compuestos heterociclicos y metodos para modular la funcion de cxcr3. |
AU780846B2 (en) * | 1999-09-16 | 2005-04-21 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
US6559188B1 (en) | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
CA2385918A1 (en) | 1999-09-28 | 2001-04-05 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Quinazolinones |
US6447772B1 (en) | 1999-10-01 | 2002-09-10 | Klaire Laboratories, Inc. | Compositions and methods relating to reduction of symptoms of autism |
JP2001172257A (ja) * | 1999-10-05 | 2001-06-26 | Fujisawa Pharmaceut Co Ltd | 有機スルホンアミド化合物 |
CA2392209A1 (en) | 1999-10-08 | 2001-04-19 | Kazuyuki Fujishima | M-substituted benzoic acid derivatives having integrin .alpha.v.beta.3 antagonistic activity |
CN100381428C (zh) * | 1999-10-27 | 2008-04-16 | 赛特凯恩蒂克公司 | 喹唑啉酮类化合物及应用 |
US7230000B1 (en) * | 1999-10-27 | 2007-06-12 | Cytokinetics, Incorporated | Methods and compositions utilizing quinazolinones |
JP2003535034A (ja) | 1999-11-12 | 2003-11-25 | ギルフォード ファーマシューティカルズ インコーポレイテッド | ジペプチジルペプチダーゼiv阻害剤並びにジペプチジルペプチダーゼiv阻害剤の製造及び使用法 |
US20040152745A1 (en) | 1999-11-12 | 2004-08-05 | Guilford Pharmaceuticals, Inc. | Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors |
US6517382B2 (en) * | 1999-12-01 | 2003-02-11 | Tyco Electronics Corporation | Pluggable module and receptacle |
US6569901B2 (en) | 2000-01-28 | 2003-05-27 | Novo Nordisk A/S | Alkynyl-substituted propionic acid derivatives, their preparation and use |
US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
US6448045B1 (en) | 2000-03-10 | 2002-09-10 | The Regents Of The University Of California | Inducing insulin gene expression in pancreas cells expressing recombinant PDX-1 |
US6608038B2 (en) | 2000-03-15 | 2003-08-19 | Novartis Ag | Methods and compositions for treatment of diabetes and related conditions via gene therapy |
EP1136482A1 (en) | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
US6555519B2 (en) | 2000-03-30 | 2003-04-29 | Bristol-Myers Squibb Company | O-glucosylated benzamide SGLT2 inhibitors and method |
US6573096B1 (en) | 2000-04-01 | 2003-06-03 | The Research Foundation At State University Of New York | Compositions and methods for inhibition of cancer invasion and angiogenesis |
US6545170B2 (en) * | 2000-04-13 | 2003-04-08 | Pharmacia Corporation | 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
ATE502941T1 (de) * | 2000-04-25 | 2011-04-15 | Icos Corp | Hemmer der menschlichen phosphatidyl-inositol-3- kinase delta |
GB0010183D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
GB0010188D0 (en) * | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
TW583185B (en) | 2000-06-13 | 2004-04-11 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same |
US6432969B1 (en) | 2000-06-13 | 2002-08-13 | Novartis Ag | N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
US6620821B2 (en) | 2000-06-15 | 2003-09-16 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
US6627636B2 (en) | 2000-06-15 | 2003-09-30 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
GB0014969D0 (en) | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
US7078397B2 (en) | 2000-06-19 | 2006-07-18 | Smithkline Beecham Corporation | Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus |
AU2001268958B2 (en) | 2000-07-04 | 2006-03-09 | Novo Nordisk A/S | Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv |
JP2002042960A (ja) * | 2000-07-25 | 2002-02-08 | Yazaki Corp | コネクタ支持機構 |
JP2004512271A (ja) | 2000-08-01 | 2004-04-22 | ファルマシア・コーポレーション | 誘導型一酸化窒素シンターゼ阻害薬としてのヘキサヒドロ−7−1h−アゼピン−2−イル−ヘキサン酸誘導体 |
ES2311532T3 (es) | 2000-08-04 | 2009-02-16 | Warner-Lambert Company Llc | 2-(4-pirdil)amino-6-dialcoxifenil-pirido(2.3-d)pirimidin-7-onas. |
JP4101053B2 (ja) * | 2000-08-10 | 2008-06-11 | 田辺三菱製薬株式会社 | プロリン誘導体及びその医薬用途 |
US20020165237A1 (en) | 2000-08-11 | 2002-11-07 | Fryburg David Albert | Treatment of the insulin resistance syndrome |
US6900226B2 (en) | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
US20020064736A1 (en) | 2000-09-27 | 2002-05-30 | Fuji Photo Film Co., Ltd. | Dye-forming coupler, silver halide photographic light-sensitive material, and method for producing an azomethine dye |
CN1257891C (zh) | 2000-10-06 | 2006-05-31 | 田边制药株式会社 | 含氮五员环化合物 |
IL155245A0 (en) | 2000-10-12 | 2003-11-23 | Ferring Bv | Novel serine protease genes related to dppiv |
IL155116A0 (en) | 2000-10-27 | 2003-10-31 | Probiodrug Ag | Pharmaceutical compositions containing as inhibitor of dipeptidyl peptidase iv and of similar enzymes |
AUPR107800A0 (en) * | 2000-10-27 | 2000-11-23 | University Of Sydney, The | Peptide and nucleic acid molecule ii |
AU2002246568A1 (en) | 2000-10-31 | 2002-08-06 | Vanderbilt University | Biological markers and diagnostic tests for angiotensin converting enzyme inhibitor- and vasopeptidase inhibitor-associated angioedema |
AU2002248221B2 (en) | 2000-10-31 | 2006-08-17 | Merck & Co., Inc. | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
WO2002038742A2 (en) | 2000-11-08 | 2002-05-16 | The University Of Georgia Research Foundation, Inc. | Dipeptidylpeptidases and methods of use |
TWI243162B (en) * | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
US20020155565A1 (en) | 2000-11-10 | 2002-10-24 | Pilar Garin-Chesa | FAP-activated anti-tumor compounds |
US20030203946A1 (en) | 2000-11-17 | 2003-10-30 | Carsten Behrens | Glucagon antagonists/inverse agonists |
MXPA03005152A (es) | 2000-12-11 | 2004-10-14 | Tularik Inc | Antogonista de cxcr3. |
JPWO2002051836A1 (ja) | 2000-12-27 | 2004-04-22 | 協和醗酵工業株式会社 | ジペプチジルペプチダーゼ−iv阻害剤 |
DE10100053A1 (de) | 2001-01-02 | 2002-08-22 | Keyneurotek Ag I G | Verwendung von Enzyminhibitoren der Dipeptidylpeptidase IV sowie der Aminopeptidase N und pharmazeutischen Zubereitungen daraus zur Prävention und/oder Therapie Ischämie-bedingter akuter und chronischer neurodegenerativer Prozesse und Erkrankungen |
DE60221098T2 (de) | 2001-02-02 | 2008-01-24 | Takeda Pharmaceutical Co. Ltd. | Kondensierte heterocyclische derivate |
CA2436738A1 (en) * | 2001-02-05 | 2002-08-15 | Dr. Reddy's Laboratories Ltd. | Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose |
KR100883277B1 (ko) * | 2001-02-24 | 2009-02-12 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 크산틴 유도체 및 이의 제조방법 |
US6337069B1 (en) | 2001-02-28 | 2002-01-08 | B.M.R.A. Corporation B.V. | Method of treating rhinitis or sinusitis by intranasally administering a peptidase |
US6371787B1 (en) * | 2001-03-07 | 2002-04-16 | International Business Machines Corporation | Pull-to-release type latch mechanism for removable small form factor electronic modules |
DK1372650T3 (da) | 2001-03-19 | 2009-03-16 | Novartis Ag | Kombinationer indeholdende et antidiarrémiddel og en epothilon eller et epothilonderivat |
US7026316B2 (en) * | 2001-03-27 | 2006-04-11 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
DE10115921A1 (de) | 2001-03-30 | 2002-10-02 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von 4,6-Diaminopyrimido[5,4-d]pyrimidinen |
GB0109146D0 (en) | 2001-04-11 | 2001-05-30 | Ferring Bv | Treatment of type 2 diabetes |
US6573287B2 (en) * | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
US20030060494A1 (en) | 2001-05-18 | 2003-03-27 | Nobuyuki Yasuda | Pharmaceutical use of N-carbamoylazole derivatives |
US7253172B2 (en) | 2001-06-20 | 2007-08-07 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
EP1406872B1 (en) | 2001-06-20 | 2007-12-19 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
ZA200300833B (en) | 2001-06-27 | 2004-02-10 | Probiodrug Ag | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents. |
ATE374181T1 (de) | 2001-06-27 | 2007-10-15 | Smithkline Beecham Corp | Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren |
DE10150203A1 (de) | 2001-10-12 | 2003-04-17 | Probiodrug Ag | Peptidylketone als Inhibitoren der DPIV |
DE60224879D1 (de) | 2001-06-27 | 2008-03-20 | Probiodrug Ag | Verwendung von dpiv-inhibitoren als therapeutika für krankhafte neurologische zustände |
EP1399433B1 (en) | 2001-06-27 | 2007-08-22 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
AU2002316437A1 (en) | 2001-06-27 | 2003-03-03 | Smithkline Beecham Corporation | Pyrrolidines as dipeptidyl peptidase inhibitors |
DE10154689A1 (de) | 2001-11-09 | 2003-05-22 | Probiodrug Ag | Substituierte Aminoketonverbindungen |
US20030144350A1 (en) | 2001-07-20 | 2003-07-31 | Adipogenix, Inc. | Fat accumulation-modulation compounds |
AU2002328946A1 (en) | 2001-08-13 | 2003-03-03 | Probiodrug Ag | Irreversible cysteine protease inhibitors of legumain |
DE10143840A1 (de) | 2001-09-06 | 2003-03-27 | Probiodrug Ag | Neue Inhibitoren der Dipeptidylpeptidase I |
WO2003024942A1 (fr) | 2001-09-14 | 2003-03-27 | Mitsubishi Pharma Corporation | Derive thiazolidine et son utilisation medicamenteuse |
US20030186963A1 (en) | 2001-09-14 | 2003-10-02 | Dorwald Florencio Zaragoza | Substituted piperidines |
JP2005509603A (ja) | 2001-09-19 | 2005-04-14 | ノボ ノルディスク アクティーゼルスカブ | Dpp−iv酵素の阻害剤であるヘテロ環化合物 |
KR100881821B1 (ko) | 2001-09-21 | 2009-02-03 | 미쓰비시 타나베 파마 코퍼레이션 | 3-치환-4-피리미돈 유도체 |
BR0212893A (pt) | 2001-09-21 | 2004-08-03 | Mitsubishi Pharma Corp | Derivados de 4-pirimidona-3-substituìdo |
AU2002341693B2 (en) | 2001-09-21 | 2008-05-29 | Bristol-Myers Squibb Holdings Ireland Unlimited Company | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors |
ATE447565T1 (de) | 2001-10-01 | 2009-11-15 | Bristol Myers Squibb Co | Spiro-hydantoin-verbindungen, die sich als entzündungshemmende mittel eignen |
WO2003030946A1 (en) | 2001-10-09 | 2003-04-17 | Novartis Ag | Regulation of insulin production |
US7064135B2 (en) | 2001-10-12 | 2006-06-20 | Novo Nordisk Inc. | Substituted piperidines |
TWI301834B (en) | 2001-10-22 | 2008-10-11 | Eisai R&D Man Co Ltd | Pyrimidone compound and pharmaceutical composition including the same |
US7060705B2 (en) * | 2001-11-07 | 2006-06-13 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
CA2467857C (en) | 2001-11-26 | 2010-08-24 | Duane A. Burnett | Piperidine-based mch antagonists for treatment of obesity and cns disorders |
EP2316470A3 (en) | 2001-11-26 | 2011-08-24 | Trustees Of Tufts College | Peptidomimetic inhibitors of post-proline cleaving enzymes |
AU2002360453C1 (en) | 2001-11-26 | 2009-06-18 | The Brigham And Women's Hospital, Inc. | Methods for treating autoimmune disorders, and reagents related thereto |
WO2003048081A2 (en) | 2001-12-04 | 2003-06-12 | Bristol-Myers Squibb Company | Glycinamides as factor xa inhibitors |
DE60222302T2 (de) * | 2001-12-06 | 2008-05-29 | Merck & Co., Inc. | Inhibitoren von mitotischem kinesin |
EP1458374A2 (en) | 2001-12-14 | 2004-09-22 | Novo Nordisk A/S | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase |
JP2005518391A (ja) | 2001-12-21 | 2005-06-23 | ノボ ノルディスク アクティーゼルスカブ | Gk活性化剤としてのアミド誘導体 |
TW200301698A (en) | 2001-12-21 | 2003-07-16 | Bristol Myers Squibb Co | Acridone inhibitors of IMPDH enzyme |
WO2003057200A2 (en) | 2002-01-11 | 2003-07-17 | Novo Nordisk A/S | Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes |
WO2003063903A2 (en) | 2002-02-01 | 2003-08-07 | Probiodrug Ag | Modulation of t lymphocytes using dp iv inhibitors |
US7101898B2 (en) | 2002-02-01 | 2006-09-05 | Novo Nordisk A/S | Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes |
WO2003068748A1 (en) | 2002-02-13 | 2003-08-21 | F. Hoffmann-La Roche Ag | Novel pyridine- and quinoline-derivatives |
DE60301491T2 (de) | 2002-02-27 | 2006-05-18 | Pfizer Products Inc., Groton | Acc-hemmer |
PL372316A1 (en) | 2002-02-28 | 2005-07-11 | Prosidion Limited | Glutaminyl based dpiv inhibitors |
DE60336901D1 (de) | 2002-03-07 | 2011-06-09 | X Ceptor Therapeutics Inc | Chinazolinon modulatoren von nukleinrezeptoren |
US20030232761A1 (en) | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
US20040106802A1 (en) * | 2002-04-08 | 2004-06-03 | Torrent Pharmaceuticals Ltd. | Novel compounds and therapeutic uses thereof |
RU2004132719A (ru) | 2002-04-08 | 2005-08-27 | Торрент Фармасьютикалз Лтд. (In) | Тиазолидин-4-карбонитрилы и их аналоги, применение указанных соединений в качестве ингибиторов дипептидилпептидаз |
JP2003300977A (ja) | 2002-04-10 | 2003-10-21 | Sumitomo Pharmaceut Co Ltd | キサンチン誘導体 |
WO2003092605A2 (en) | 2002-04-30 | 2003-11-13 | Trustees Of Tufts College | Protease inhibitors |
TW200307667A (en) * | 2002-05-06 | 2003-12-16 | Bristol Myers Squibb Co | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
US7057046B2 (en) * | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
ATE478867T1 (de) * | 2002-05-23 | 2010-09-15 | Novartis Vaccines & Diagnostic | Substituierte quinazolinone verbindungen |
GB0212412D0 (en) | 2002-05-29 | 2002-07-10 | Novartis Ag | Combination of organic compounds |
WO2003101449A2 (en) | 2002-06-04 | 2003-12-11 | Pfizer Products Inc. | Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof |
US20040009972A1 (en) * | 2002-06-17 | 2004-01-15 | Ding Charles Z. | Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase |
WO2003106416A2 (en) | 2002-06-17 | 2003-12-24 | Smithkline Beecham Corporation | Chemical process |
SE0201976D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
DK1528931T3 (da) | 2002-08-09 | 2008-09-08 | Prosidion Ltd | Dipeptidylpeptidase-IV-inhibitorer til reduktion af hastigheden af kronisk vægtforögelse |
US7407955B2 (en) * | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US20040048853A1 (en) * | 2002-08-21 | 2004-03-11 | Gustave Bergnes | Compounds, compositions, and methods |
US7495005B2 (en) | 2002-08-22 | 2009-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, their preparation and their use in pharmaceutical compositions |
DE10238477A1 (de) * | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
US6998502B1 (en) | 2002-09-05 | 2006-02-14 | Sabinsa Corporation | Convenient process of manufacture for difluoromethylornithine and related compounds |
EP1407774A1 (en) * | 2002-09-10 | 2004-04-14 | LION Bioscience AG | 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds |
EP1398032A1 (en) | 2002-09-10 | 2004-03-17 | PheneX Pharmaceuticals AG | 4-Oxo-quinazolines as LXR nuclear receptor binding compounds |
JP2004123738A (ja) | 2002-09-11 | 2004-04-22 | Takeda Chem Ind Ltd | 徐放性製剤 |
DE60331747D1 (de) | 2002-09-18 | 2010-04-29 | Prosidion Ltd | Sekundäre bindungsstelle von dipeptidylpeptidase iv (dp iv) |
US7262207B2 (en) | 2002-09-19 | 2007-08-28 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
US6869966B2 (en) * | 2002-09-30 | 2005-03-22 | Banyu Pharmaceutical Co., Ltd. | N-substituted-2-oxodihydropyridine derivatives |
AU2003298596B2 (en) | 2002-10-18 | 2008-12-18 | Merck Sharp & Dohme Corp. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
DE60332856D1 (de) | 2002-10-23 | 2010-07-15 | Bristol Myers Squibb Co | Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv |
US7482337B2 (en) | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
DE10254304A1 (de) | 2002-11-21 | 2004-06-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
DE10256264A1 (de) | 2002-12-03 | 2004-06-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Imidazo-pyridinone und Imidazo-pyridazinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
UY28103A1 (es) * | 2002-12-03 | 2004-06-30 | Boehringer Ingelheim Pharma | Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos |
US7135467B2 (en) | 2003-01-13 | 2006-11-14 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
US7148246B2 (en) | 2003-02-27 | 2006-12-12 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals |
PL1601673T3 (pl) * | 2003-03-07 | 2009-10-30 | Astrazeneca Ab | Skondensowane heterocykle i ich zastosowania |
US20040242566A1 (en) | 2003-03-25 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
TWI357408B (en) | 2003-03-26 | 2012-02-01 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
EP1622870A2 (en) | 2003-05-05 | 2006-02-08 | Prosidion Ltd. | Glutaminyl based dp iv-inhibitors |
JP4806628B2 (ja) | 2003-05-05 | 2011-11-02 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤 |
EP1625122A1 (en) | 2003-05-14 | 2006-02-15 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
ATE437876T1 (de) | 2003-06-20 | 2009-08-15 | Hoffmann La Roche | Hexahydropyridoisochinoline als dpp-iv- inhibitoren |
DE602004030244D1 (de) | 2003-06-20 | 2011-01-05 | Hoffmann La Roche | Itoren |
US7579357B2 (en) | 2003-08-13 | 2009-08-25 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2005026148A1 (en) | 2003-09-08 | 2005-03-24 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
US20050065144A1 (en) | 2003-09-08 | 2005-03-24 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
MXPA06005736A (es) * | 2003-11-19 | 2006-12-14 | Chiron Corp | Compuestos de quinazolinona con bioacumulacion reducida. |
EP1713780B1 (en) | 2004-02-05 | 2012-01-18 | Probiodrug AG | Novel inhibitors of glutaminyl cyclase |
BRPI0418639B8 (pt) | 2004-03-15 | 2021-05-25 | Takeda Pharmaceutical | compostos inibidores de dipeptidil peptidase, assim como composição farmacêutica contendo os mesmos |
EP1828192B1 (en) | 2004-12-21 | 2014-12-03 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
-
2004
- 2004-03-24 US US10/809,638 patent/US20040242566A1/en not_active Abandoned
- 2004-03-24 CA CA002518465A patent/CA2518465A1/en not_active Abandoned
- 2004-03-24 JP JP2006509315A patent/JP4887139B2/ja not_active Expired - Fee Related
- 2004-03-24 US US10/809,637 patent/US7687625B2/en not_active Expired - Fee Related
- 2004-03-24 US US10/809,636 patent/US20040242568A1/en not_active Abandoned
- 2004-03-24 CN CNA2004800119000A patent/CN1894234A/zh active Pending
- 2004-03-24 US US10/809,635 patent/US7550590B2/en not_active Expired - Fee Related
- 2004-03-24 EP EP04758366A patent/EP1608317B1/en not_active Expired - Lifetime
- 2004-03-24 KR KR1020057018103A patent/KR20050122220A/ko not_active Application Discontinuation
- 2004-03-24 WO PCT/US2004/009217 patent/WO2004087053A2/en active Search and Examination
Patent Citations (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3960949A (en) * | 1971-04-02 | 1976-06-01 | Schering Aktiengesellschaft | 1,2-Biguanides |
US3823135A (en) * | 1972-12-26 | 1974-07-09 | Shell Oil Co | Pyrimidone herbicides |
US4494978A (en) * | 1976-12-30 | 1985-01-22 | Chevron Research Company | Herbicidal N-(N'-hydrocarbyloxycarbamylalkyl)-2,6-dialkyl-alpha-haloacetanilides |
US5614492A (en) * | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US4935493A (en) * | 1987-10-06 | 1990-06-19 | E. I. Du Pont De Nemours And Company | Protease inhibitors |
US5433955A (en) * | 1989-01-23 | 1995-07-18 | Akzo N.V. | Site specific in vivo activation of therapeutic drugs |
US5387512A (en) * | 1991-06-07 | 1995-02-07 | Merck & Co. Inc. | Preparation of 3-[z-benzoxazol-2-yl)ethyl]-5-(1-hydroxyethyl)-6-methyl-2-(1H)-pyridinone by biotransformation |
US5624894A (en) * | 1992-09-17 | 1997-04-29 | University Of Florida | Brain-enhanced delivery of neuroactive peptides by sequential metabolism |
US6201132B1 (en) * | 1993-12-03 | 2001-03-13 | Ferring B.V. | Inhibitors of DP-mediated processes, compositions, and therapeutic methods thereof |
US6090786A (en) * | 1994-06-10 | 2000-07-18 | Fondatech Benelux N.V. | Serine proteases, their activity and their synthetic inhibitors |
US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5614379A (en) * | 1995-04-26 | 1997-03-25 | Eli Lilly And Company | Process for preparing anti-obesity protein |
US6265551B1 (en) * | 1995-06-01 | 2001-07-24 | Dana-Farber Cancer Institute, Inc. | Form of dipeptidylpeptidase IV (CD26) found in human serum, antibodies thereto, and uses thereof |
US5885997A (en) * | 1996-07-01 | 1999-03-23 | Dr. Reddy's Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
US20030060434A1 (en) * | 1997-02-18 | 2003-03-27 | Loretta Nielsen | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms |
US6235493B1 (en) * | 1997-08-06 | 2001-05-22 | The Regents Of The University Of California | Amino acid substituted-cresyl violet, synthetic fluorogenic substrates for the analysis of agents in individual in vivo cells or tissue |
US6258597B1 (en) * | 1997-09-29 | 2001-07-10 | Point Therapeutics, Inc. | Stimulation of hematopoietic cells in vitro |
US6703238B2 (en) * | 1997-09-29 | 2004-03-09 | Point Therapeutics, Inc. | Methods for expanding antigen-specific T cells |
US20030027282A1 (en) * | 1997-10-06 | 2003-02-06 | Huber Brigitte T. | Quiescent cell dipeptidyl peptidase: a novel cytoplasmic serine protease |
US6214340B1 (en) * | 1997-11-18 | 2001-04-10 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Physiologically active substance sulphostin, process for producing the same, and use thereof |
US20030008925A1 (en) * | 1997-11-19 | 2003-01-09 | Marc Esteve | Treatment of drug-induced sleepiness |
US20030045464A1 (en) * | 1997-12-16 | 2003-03-06 | Hermeling Ronald Norbert | Glucagon-like peptide-1 crystals |
US6184020B1 (en) * | 1997-12-16 | 2001-02-06 | Novo Nordisk Biotech, Inc. | Polypeptides having aminopeptidase activity and nucleic acids encoding same |
US20020061839A1 (en) * | 1998-03-09 | 2002-05-23 | Scharpe Simon Lodewijk | Serine peptidase modulators |
US6548481B1 (en) * | 1998-05-28 | 2003-04-15 | Probiodrug Ag | Effectors of dipeptidyl peptidase IV |
US20030134802A1 (en) * | 1998-05-28 | 2003-07-17 | Hans-Ulrich Demuth | Novel effectors of dipepetidyl peptidase IV |
US6355614B1 (en) * | 1998-06-05 | 2002-03-12 | Point Therapeutics | Cyclic boroproline compounds |
US20020049164A1 (en) * | 1998-06-24 | 2002-04-25 | Hans-Ulrich Demuth | Prodrugs of DP IV-inhibitors |
US20020071838A1 (en) * | 1998-07-31 | 2002-06-13 | Hans-Ulrich Demuth | Method for raising the blood glucose level in mammals |
US20020006899A1 (en) * | 1998-10-06 | 2002-01-17 | Pospisilik Andrew J. | Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals |
US20020049153A1 (en) * | 1999-05-17 | 2002-04-25 | BRIDON Dominique P. | Long lasting insulinoptropic peptides |
US20020082427A1 (en) * | 1999-06-10 | 2002-06-27 | Hans-Ulrich Demuth | Method for the production of thiazolidin |
US6172081B1 (en) * | 1999-06-24 | 2001-01-09 | Novartis Ag | Tetrahydroisoquinoline 3-carboxamide derivatives |
US20030092630A2 (en) * | 1999-08-24 | 2003-05-15 | Probiodrug Ag | New effectors of dipeptidyl peptidase iv for topical use |
US20030087935A1 (en) * | 1999-09-22 | 2003-05-08 | Cheng Peter T. | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
US6727271B2 (en) * | 1999-09-22 | 2004-04-27 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
US20030096846A1 (en) * | 1999-09-22 | 2003-05-22 | Cheng Peter T. | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
US6251391B1 (en) * | 1999-10-01 | 2001-06-26 | Klaire Laboratories, Inc. | Compositions containing dipepitidyl peptidase IV and tyrosinase or phenylalaninase for reducing opioid-related symptons |
US6261794B1 (en) * | 1999-10-14 | 2001-07-17 | Saint Louis University | Methods for identifying inhibitors of methionine aminopeptidases |
US20030096857A1 (en) * | 1999-11-30 | 2003-05-22 | Evans David Michael | Novel antidiabetic agents |
US20030040478A1 (en) * | 1999-12-08 | 2003-02-27 | Drucker Daniel J | Chemotherapy treatment |
US6380398B2 (en) * | 2000-01-04 | 2002-04-30 | Novo Nordisk A/S | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
US20030139434A1 (en) * | 2000-01-21 | 2003-07-24 | Bork Balkan | Combinations comprising dipeptidylpeptidase-iv inhibitor |
US20030060412A1 (en) * | 2000-01-27 | 2003-03-27 | Prouty Walter Francis | Process for solubilizing glucagon-like peptide 1compounds |
US20020019411A1 (en) * | 2000-03-10 | 2002-02-14 | Robl Jeffrey A. | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
US20030008905A1 (en) * | 2000-03-31 | 2003-01-09 | Hans-Ulrich Demuth | Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
US20020041871A1 (en) * | 2000-06-01 | 2002-04-11 | Brudnak Mark A. | Genomeceutical and/or enzymatic composition and method for treating autism |
US20020037829A1 (en) * | 2000-08-23 | 2002-03-28 | Aronson Peter S. | Use of DPPIV inhibitors as diuretic and anti-hypertensive agents |
US20020082292A1 (en) * | 2000-09-27 | 2002-06-27 | Sahoo Soumya P. | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
US6686337B2 (en) * | 2000-10-30 | 2004-02-03 | Ortho-Mcneil Pharmaceutical, Inc. | Combination therapy comprising anti-diabetic and anticonvulsant agents |
US20030055052A1 (en) * | 2000-11-10 | 2003-03-20 | Stefan Peters | FAP-activated anti-tumor compounds |
US20020077340A1 (en) * | 2000-11-20 | 2002-06-20 | Richard Sulsky | Pyridone inhibitors of fatty acid binding protein and method |
US20040138148A1 (en) * | 2001-02-14 | 2004-07-15 | Nobuhiko Fushimi | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof |
US6716843B2 (en) * | 2001-03-28 | 2004-04-06 | Les Laboratoires Servier | Alpha-amino acid sulphonyl compounds |
US20030087950A1 (en) * | 2001-03-28 | 2003-05-08 | Denanteuil Guillaume | New alpha-amino acid sulphonyl compounds |
US20030119736A1 (en) * | 2001-04-02 | 2003-06-26 | Hans-Ulrich Demuth | Methods for improving islet signaling in diabetes mellitus and for its prevention |
US20030103968A1 (en) * | 2001-04-12 | 2003-06-05 | Andree Amelsberg | Use of alpha specific antibody BIBH1 in the treatment of cancer |
US6706742B2 (en) * | 2001-05-15 | 2004-03-16 | Les Laboratories Servier | Alpha-amino-acid compounds |
US20030092697A1 (en) * | 2001-05-30 | 2003-05-15 | Cheng Peter T. | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
US20030069234A1 (en) * | 2001-06-06 | 2003-04-10 | Medina Julio C. | CXCR3 antagonists |
US6710843B2 (en) * | 2001-06-19 | 2004-03-23 | Samsung Electronics Co., Ltd. | In-line system and method for manufacturing liquid crystal display |
US20030130199A1 (en) * | 2001-06-27 | 2003-07-10 | Von Hoersten Stephan | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
US20030135023A1 (en) * | 2001-06-27 | 2003-07-17 | Hans-Ulrich Demuth | Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis |
US20030119750A1 (en) * | 2001-06-27 | 2003-06-26 | Hans-Ulrich Demuth | Use of dipeptidyl peptidase IV inhibitors |
US20030105077A1 (en) * | 2001-07-03 | 2003-06-05 | Kanstrup Anders Bendtz | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
US20030100563A1 (en) * | 2001-07-06 | 2003-05-29 | Edmondson Scott D. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
US6699871B2 (en) * | 2001-07-06 | 2004-03-02 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
US6747035B2 (en) * | 2001-08-13 | 2004-06-08 | Warner-Lambert Llc | 1-alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors |
US20030119738A1 (en) * | 2001-09-06 | 2003-06-26 | Andre Niestroj | Novel inhibitors of dipeptidyl peptidase I |
US6673829B2 (en) * | 2001-09-14 | 2004-01-06 | Novo Nordisk A/S | Aminoazetidine,-pyrrolidine and -piperidine derivatives |
US20030139429A1 (en) * | 2001-09-27 | 2003-07-24 | Cohen David Saul | Combinations |
US20050043299A1 (en) * | 2001-10-23 | 2005-02-24 | Ferring B. V. | Inhibitors of dipeptidyl peptidase iv |
US6861440B2 (en) * | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
US20030130281A1 (en) * | 2001-10-26 | 2003-07-10 | Markus Boehringer | DPP IV inhibitors |
US6673815B2 (en) * | 2001-11-06 | 2004-01-06 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
US20030130306A1 (en) * | 2001-11-06 | 2003-07-10 | Pratik Devasthale | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
US20050014946A1 (en) * | 2001-11-09 | 2005-01-20 | Hans-Ulrich Demuth | Substituted amino ketone compounds |
US20030125304A1 (en) * | 2001-11-09 | 2003-07-03 | Hans-Ulrich Demuth | Substituted amino ketone compounds |
US20030089935A1 (en) * | 2001-11-13 | 2003-05-15 | Macronix International Co., Ltd. | Non-volatile semiconductor memory device with multi-layer gate insulating structure |
US6727261B2 (en) * | 2001-12-27 | 2004-04-27 | Hoffman-La Roche Inc. | Pyrido[2,1-A]Isoquinoline derivatives |
US20030144206A1 (en) * | 2001-12-29 | 2003-07-31 | Knudsen Lotte Bjerre | Combined use of a GLP-1 compound and modulator of diabetic late complications |
US6867205B2 (en) * | 2002-02-13 | 2005-03-15 | Hoffman-La Roche Inc. | Pyridine and pyrimidine derivatives |
US6710040B1 (en) * | 2002-06-04 | 2004-03-23 | Pfizer Inc. | Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors |
US20040132713A1 (en) * | 2002-06-04 | 2004-07-08 | Pfizer Inc | Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors |
US20040116328A1 (en) * | 2002-06-06 | 2004-06-17 | Eisai Co., Ltd. | Condensed imidazole derivatives |
US20040054171A1 (en) * | 2002-07-04 | 2004-03-18 | Jensen Anette Frost | Polymorphic forms of a 4H-thieno[3,2-E]-1,2,4-thiadiazine 1,1-dioxide derivative |
US20040058876A1 (en) * | 2002-09-18 | 2004-03-25 | Torsten Hoffmann | Secondary binding site of dipeptidyl peptidase IV (DP IV) |
US20040132732A1 (en) * | 2002-10-21 | 2004-07-08 | Wei Han | Quinazolinones and derivatives thereof as factor Xa inhibitors |
US20040110817A1 (en) * | 2002-11-18 | 2004-06-10 | Pfizer Inc | Dipeptidyl peptidase IV inhibiting fluorinated cyclic amides |
US20050020574A1 (en) * | 2002-12-03 | 2005-01-27 | Boehringer Ingelheim Pharma Gmbh Co. Kg | New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions |
US20050014732A1 (en) * | 2003-03-14 | 2005-01-20 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and an anti-diabetic agent |
US20050058635A1 (en) * | 2003-05-05 | 2005-03-17 | Hans-Ulrich Demuth | Use of effectors of glutaminyl and glutamate cyclases |
US20050026921A1 (en) * | 2003-06-18 | 2005-02-03 | Boehringer Ingelheim International Gmbh | New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
US20050032804A1 (en) * | 2003-06-24 | 2005-02-10 | Cypes Stephen Howard | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
US20050038020A1 (en) * | 2003-08-01 | 2005-02-17 | Hamann Lawrence G. | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
US20050043292A1 (en) * | 2003-08-20 | 2005-02-24 | Pfizer Inc | Fluorinated lysine derivatives as dipeptidyl peptidase IV inhibitors |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7687625B2 (en) | 2003-03-25 | 2010-03-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7723344B2 (en) | 2003-08-13 | 2010-05-25 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7790736B2 (en) | 2003-08-13 | 2010-09-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7790734B2 (en) | 2003-09-08 | 2010-09-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US8288539B2 (en) | 2004-03-15 | 2012-10-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US8173663B2 (en) | 2004-03-15 | 2012-05-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7781584B2 (en) | 2004-03-15 | 2010-08-24 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US8329900B2 (en) | 2004-03-15 | 2012-12-11 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US8188275B2 (en) | 2004-03-15 | 2012-05-29 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7807689B2 (en) | 2004-03-15 | 2010-10-05 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7906523B2 (en) | 2004-03-15 | 2011-03-15 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7687638B2 (en) | 2004-06-04 | 2010-03-30 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
US7825242B2 (en) | 2004-07-16 | 2010-11-02 | Takeda Pharmaceutical Company Limted | Dipeptidyl peptidase inhibitors |
US7872124B2 (en) | 2004-12-21 | 2011-01-18 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US8906901B2 (en) | 2005-09-14 | 2014-12-09 | Takeda Pharmaceutical Company Limited | Administration of dipeptidyl peptidase inhibitors |
US8222411B2 (en) | 2005-09-16 | 2012-07-17 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7960384B2 (en) | 2006-03-28 | 2011-06-14 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US8003656B2 (en) | 2006-08-23 | 2011-08-23 | Neurogen Corporation | 2-phenoxy pyrimidinone analogues |
US20090069347A1 (en) * | 2006-08-23 | 2009-03-12 | Neurogen Corporation | 2-phenoxy pyrimidinone analogues |
US20080090845A1 (en) * | 2006-08-23 | 2008-04-17 | Neurogen Corporation | Haloalkyl-substituted pyrimidinone derivatives |
US8759361B2 (en) | 2006-08-23 | 2014-06-24 | Neurogen Corporation | 2-phenoxy pyrimidinone analogues |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
US8084605B2 (en) | 2006-11-29 | 2011-12-27 | Kelly Ron C | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
US20090257979A1 (en) * | 2008-04-15 | 2009-10-15 | Intermune, Inc. | Novel Inhibitors of Hepatitis C Virus Replication |
US20110110890A1 (en) * | 2009-11-09 | 2011-05-12 | Intermune, Inc. | Novel Inhibitors of Hepatitis C Virus Replication |
US10555929B2 (en) | 2015-03-09 | 2020-02-11 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US10772865B2 (en) | 2015-03-09 | 2020-09-15 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US11400072B2 (en) | 2015-03-09 | 2022-08-02 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US11253508B2 (en) | 2017-04-03 | 2022-02-22 | Coherus Biosciences, Inc. | PPARy agonist for treatment of progressive supranuclear palsy |
Also Published As
Publication number | Publication date |
---|---|
JP2007524600A (ja) | 2007-08-30 |
JP4887139B2 (ja) | 2012-02-29 |
WO2004087053A2 (en) | 2004-10-14 |
US20050004117A1 (en) | 2005-01-06 |
CN1894234A (zh) | 2007-01-10 |
WO2004087053A9 (en) | 2004-11-11 |
US7687625B2 (en) | 2010-03-30 |
KR20050122220A (ko) | 2005-12-28 |
CA2518465A1 (en) | 2004-10-14 |
EP1608317A2 (en) | 2005-12-28 |
US7550590B2 (en) | 2009-06-23 |
US20040242568A1 (en) | 2004-12-02 |
US20040259870A1 (en) | 2004-12-23 |
EP1608317B1 (en) | 2012-09-26 |
EP1608317A4 (en) | 2006-12-27 |
WO2004087053A3 (en) | 2006-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7550590B2 (en) | Dipeptidyl peptidase inhibitors | |
US7872124B2 (en) | Dipeptidyl peptidase inhibitors | |
US7825242B2 (en) | Dipeptidyl peptidase inhibitors | |
EP1506967B1 (en) | Dipeptidyl peptidase inhibitors | |
US7960384B2 (en) | Dipeptidyl peptidase inhibitors | |
EP1699777B1 (en) | Dipeptidyl peptidase inhibitors | |
US20050250829A1 (en) | Kinase inhibitors | |
WO2005095381A1 (en) | Dipeptidyl peptidase inhibitors | |
US7550598B2 (en) | Kinase inhibitors | |
EP1911754B1 (en) | Dipeptidyl peptidase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SYNX, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FENG, JUN;GWALTNEY, STEPHEN L.;KALDOR, STEPHEN W.;AND OTHERS;REEL/FRAME:015654/0194;SIGNING DATES FROM 20040709 TO 20040802 |
|
AS | Assignment |
Owner name: QUALCOMM, INCORPORATED, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SUTIVONG, ARAK;NAGUIB, AYMAN FAWAY;ARGAWAL, AVNEESH;REEL/FRAME:015069/0566;SIGNING DATES FROM 20040617 TO 20040630 |
|
AS | Assignment |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED,JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TAKEDA SAN DIEGO, INC.;REEL/FRAME:017182/0232 Effective date: 20060111 Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TAKEDA SAN DIEGO, INC.;REEL/FRAME:017182/0232 Effective date: 20060111 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |